| Year |
Citation |
Score |
| 2022 |
Hendrix N, Oestreicher N, Lalla D, Dolan CM, Fisher KA, Veenstra DL, Moy B. Residual Disease Burden After Neoadjuvant Therapy Among US Patients With High-Risk HER2-positive Early-Stage Breast Cancer: A Population Effectiveness Model. Clinical Breast Cancer. PMID 36220724 DOI: 10.1016/j.clbc.2022.08.012 |
0.606 |
|
| 2021 |
Hendrix N, Veenstra DL, Cheng M, Anderson NC, Verguet S. Assessing the Economic Value of Clinical Artificial Intelligence: Challenges and Opportunities. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 25: 331-339. PMID 35227443 DOI: 10.1016/j.jval.2021.08.015 |
0.533 |
|
| 2020 |
Neuberger EE, Carlson JJ, Veenstra DL. Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome. Pharmacoeconomics. PMID 32715412 DOI: 10.1007/S40273-020-00945-Z |
0.337 |
|
| 2020 |
Dhanda DS, Veenstra DL, Regier DA, Basu A, Carlson JJ. Payer Preferences and Willingness to Pay for Genomic Precision Medicine: A Discrete Choice Experiment. Journal of Managed Care & Specialty Pharmacy. 26: 529-537. PMID 32223606 DOI: 10.18553/Jmcp.2020.26.4.529 |
0.391 |
|
| 2020 |
Veenstra DL, Mandelblatt J, Neumann P, Basu A, Peterson JF, Ramsey SD. Health Economics Tools and Precision Medicine: Opportunities and Challenges. Forum For Health Economics & Policy. PMID 32134729 DOI: 10.1515/Fhep-2019-0013 |
0.351 |
|
| 2020 |
Basu A, Carlson J, Veenstra D. Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 23: 96-103. PMID 31952678 DOI: 10.1016/J.Jval.2019.10.014 |
0.32 |
|
| 2019 |
Guzauskas GF, Basu A, Carlson JJ, Veenstra DL. Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 988-994. PMID 31511188 DOI: 10.1016/J.Jval.2019.03.023 |
0.313 |
|
| 2019 |
Niu X, Amendola LM, Hart R, Bennette CS, Heagerty P, Horike-Pyne M, Trinidad SB, Rosenthal EA, Comstock B, Nefcy C, Hisama FM, Bennett RL, Grady WM, Gallego CJ, Tarczy-Hornoch P, ... ... Veenstra DL, et al. Clinical exome sequencing vs. usual care for hereditary colorectal cancer diagnosis: A pilot comparative effectiveness study. Contemporary Clinical Trials. 84: 105820. PMID 31400517 DOI: 10.1016/J.Cct.2019.105820 |
0.357 |
|
| 2019 |
Veenstra DL, Guzauskas G, Peterson J, Hassen DA, Snyder S, Hao J, Williams M. Cost-effectiveness of population genomic screening. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 31303645 DOI: 10.1038/S41436-019-0580-4 |
0.332 |
|
| 2019 |
Li M, Basu A, Bennette C, Veenstra D, Garrison LP. How Does Option Value Affect the Potential Cost-Effectiveness of a Treatment? The Case of Ipilimumab for Metastatic Melanoma. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 22: 777-784. PMID 31277824 DOI: 10.1016/J.Jval.2019.02.002 |
0.358 |
|
| 2019 |
Li M, Basu A, Bennette CS, Veenstra DL, Garrison LP. Do cancer treatments have option value? Real-world evidence from metastatic melanoma. Health Economics. 28: 855-867. PMID 31237095 DOI: 10.1002/Hec.3899 |
0.307 |
|
| 2019 |
Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL. Correction to: Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics. PMID 31089966 DOI: 10.1007/S40273-019-00809-1 |
0.644 |
|
| 2019 |
Li M, Bennette CS, Amendola LM, Ragan Hart M, Heagerty P, Comstock B, Tarczy-Hornoch P, Fullerton SM, Regier DA, Burke W, Trinidad SB, Jarvik GP, Veenstra DL, Patrick DL. The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation. Journal of Genetic Counseling. 28: 477-490. PMID 30964586 DOI: 10.1007/S10897-018-0286-9 |
0.312 |
|
| 2019 |
Guzauskas GF, Masaquel A, Thuresson PO, Dawson K, Veenstra DL. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States. Leukemia & Lymphoma. 1-9. PMID 30632837 DOI: 10.1080/10428194.2018.1551532 |
0.34 |
|
| 2019 |
Spencer S, Veenstra DL, Guzauskas G. Pcv58 Cost-Effectiveness Of Population-Wide Genomic Screening For Familial Hypercholesterolemia Value in Health. 22. DOI: 10.1016/J.Jval.2019.04.494 |
0.318 |
|
| 2019 |
Guzauskas G, Spencer S, Veenstra DL. Ppm5 Timing And The Cost-Effectiveness Of Population-Wide Genomic Screening For Breast And Ovarian Cancer Value in Health. 22. DOI: 10.1016/J.Jval.2019.04.1628 |
0.322 |
|
| 2018 |
Hendrix N, Ollendorf DA, Chapman RH, Loos A, Liu S, Kumar V, Linder JA, Pearson SD, Veenstra DL. Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis. Journal of Managed Care & Specialty Pharmacy. 24: 1210-1217. PMID 30479197 DOI: 10.18553/Jmcp.2018.24.12.1210 |
0.306 |
|
| 2018 |
Hart MR, Biesecker BB, Blout CL, Christensen KD, Amendola LM, Bergstrom KL, Biswas S, Bowling KM, Brothers KB, Conlin LK, Cooper GM, Dulik MC, East KM, Everett JN, Finnila CR, ... ... Veenstra DL, et al. Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 30287922 DOI: 10.1038/S41436-018-0308-X |
0.337 |
|
| 2018 |
Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, Pitt B, Hauptman PJ, Veenstra DL. Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia. Pharmacoeconomics. PMID 30194623 DOI: 10.1007/S40273-018-0709-3 |
0.662 |
|
| 2018 |
Amendola LM, Berg JS, Horowitz CR, Angelo F, Bensen JT, Biesecker BB, Biesecker LG, Cooper GM, East K, Filipski K, Fullerton SM, Gelb BD, Goddard KAB, Hailu B, Hart R, ... ... Veenstra DL, et al. The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations. American Journal of Human Genetics. 103: 319-327. PMID 30193136 DOI: 10.1016/J.Ajhg.2018.08.007 |
0.321 |
|
| 2018 |
Carlson JJ, Kim DD, Guzauskas GF, Bennette CS, Veenstra DL, Basu A, Hendrix N, Hershman DL, Baker L, Ramsey SD. Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study. Cancer Medicine. PMID 30030904 DOI: 10.1002/Cam4.1657 |
0.308 |
|
| 2018 |
Weymann D, Veenstra DL, Jarvik GP, Regier DA. Patient preferences for massively parallel sequencing genetic testing of colorectal cancer risk: a discrete choice experiment. European Journal of Human Genetics : Ejhg. PMID 29802320 DOI: 10.1038/S41431-018-0161-Z |
0.376 |
|
| 2017 |
Carlson JJ, Kim D, Guzauskas GF, Bennette CS, Hershman DL, Baker LH, Hendrix N, Basu A, Veenstra DL, Ramsey S. Impact of value of research analyses on SWOG’s clinical trial capsule scoring. Journal of Clinical Oncology. 35: e18311-e18311. DOI: 10.1200/Jco.2017.35.15_Suppl.E18311 |
0.301 |
|
| 2017 |
Guzauskas GF, Masaquel A, Thuresson P, Li J, Reyes CM, Veenstra D. Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US? Blood. 130: 5603-5603. DOI: 10.1182/Blood.V130.Suppl_1.5603.5603 |
0.371 |
|
| 2016 |
Serbin MA, Guzauskas GF, Veenstra DL. Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis. Journal of Managed Care & Specialty Pharmacy. 22: 939-47. PMID 27459657 DOI: 10.18553/Jmcp.2016.22.8.939 |
0.304 |
|
| 2016 |
Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, ... ... Veenstra DL, et al. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics. PMID 27181682 DOI: 10.1016/J.Ajhg.2016.04.011 |
0.336 |
|
| 2016 |
Bennette CS, Veenstra DL, Basu A, Baker LH, Ramsey SD, Carlson JJ. Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. Medical Decision Making : An International Journal of the Society For Medical Decision Making. PMID 27012232 DOI: 10.1177/0272989X16636847 |
0.31 |
|
| 2016 |
Guzauskas GF, Masaquel A, Reyes C, Wilhelm K, Krivasi T, Veenstra DL. What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US? Blood. 128: 3605-3605. DOI: 10.1182/Blood.V128.22.3605.3605 |
0.341 |
|
| 2016 |
Veenstra DL. The value of routine pharmacogenomic screening - Are we there yet? A perspective on the costs and benefits of routine screening - Shouldn't everyone have this done? Clinical Pharmacology and Therapeutics. 99: 164-166. DOI: 10.1002/Cpt.299 |
0.392 |
|
| 2015 |
Gallego CJ, Perez ML, Burt A, Amendola LM, Shirts BH, Pritchard CC, Hisama FM, Bennett RL, Veenstra DL, Jarvik GP. Next Generation Sequencing in the Clinic: a Patterns of Care Study in a Retrospective Cohort of Subjects Referred to a Genetic Medicine Clinic for Suspected Lynch Syndrome. Journal of Genetic Counseling. PMID 26637299 DOI: 10.1007/S10897-015-9902-0 |
0.371 |
|
| 2015 |
Canestaro WJ, Pritchard DE, Garrison LP, Dubois R, Veenstra DL. Improving the Efficiency and Quality of the Value Assessment Process for Companion Diagnostic Tests: The Companion test Assessment Tool (CAT). Journal of Managed Care & Specialty Pharmacy. 21: 700-12. PMID 26233542 DOI: 10.18553/Jmcp.2015.21.8.700 |
0.33 |
|
| 2015 |
Gallego CJ, Shirts BH, Bennette CS, Guzauskas G, Amendola LM, Horike-Pyne M, Hisama FM, Pritchard CC, Grady WM, Burke W, Jarvik GP, Veenstra DL. Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2084-91. PMID 25940718 DOI: 10.1200/Jco.2014.59.3665 |
0.352 |
|
| 2015 |
Sullivan SD, Yeung K, Vogeler C, Ramsey SD, Wong E, Murphy CO, Danielson D, Veenstra DL, Garrison LP, Burke W, Watkins JB. Design, implementation, and first-year outcomes of a value-based drug formulary. Journal of Managed Care & Specialty Pharmacy. 21: 269-75. PMID 25803760 DOI: 10.18553/Jmcp.2015.21.4.269 |
0.332 |
|
| 2015 |
Bennette CS, Gallego CJ, Burke W, Jarvik GP, Veenstra DL. The cost-effectiveness of returning incidental findings from next-generation genomic sequencing. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 17: 587-95. PMID 25394171 DOI: 10.1038/Gim.2014.156 |
0.343 |
|
| 2015 |
Ramsey SD, Henry NL, Gralow JR, Mirick DK, Barlow W, Etzioni R, Mummy D, Thariani R, Veenstra DL. Tumor marker usage and medical care costs among older early-stage breast cancer survivors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 149-55. PMID 25332254 DOI: 10.1200/Jco.2014.55.5409 |
0.307 |
|
| 2015 |
Williams JK, Cashion AK, Veenstra DL. Challenges in evaluating next-generation sequence data for clinical decisions. Nursing Outlook. 63: 48-50. PMID 25261386 DOI: 10.1016/J.Outlook.2014.08.007 |
0.344 |
|
| 2015 |
Bennette CS, Ramsey SD, Veenstra DL, Basu A, Carlson JJ. Value of information analyses for real-time prioritization decisions within a cancer clinical trials cooperative group. Journal of Clinical Oncology. 33: 6506-6506. DOI: 10.1200/Jco.2015.33.15_Suppl.6506 |
0.323 |
|
| 2014 |
Gallego CJ, Bennette CS, Heagerty P, Comstock B, Horike-Pyne M, Hisama F, Amendola LM, Bennett RL, Dorschner MO, Tarczy-Hornoch P, Grady WM, Fullerton SM, Trinidad SB, Regier DA, Nickerson DA, ... ... Veenstra DL, et al. Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes. Contemporary Clinical Trials. 39: 1-8. PMID 24997220 DOI: 10.1016/J.Cct.2014.06.016 |
0.39 |
|
| 2014 |
Veenstra DL, Reyes CM, Ramsey SD. Is obinutuzumab cost-effective in the first-line treatment of CLL? Journal of Clinical Oncology. 32: 7052-7052. DOI: 10.1200/Jco.2014.32.15_Suppl.7052 |
0.38 |
|
| 2014 |
Reyes C, Gazauskas G, Becker U, Moreno S, Veenstra DL. Cost-Effectiveness Analysis of Obinutuzumab Versus Ofatumumab for Previously Untreated Chronic Lymphocytic Leukemia (CLL) Blood. 124: 1324-1324. DOI: 10.1182/Blood.V124.21.1324.1324 |
0.374 |
|
| 2014 |
Guzauskas GF, Villa KF, Vanhove TF, Veenstra DL. Risk-Benefit Trade-Off of Pediatric-Inspired Versus Hyper-CVAD Protocols for Philadelphia Negative Acute Lymphocytic Leukemia (ALL) in Adolescents and Young Adults: A Modeling Analysis Blood. 124: 1281-1281. DOI: 10.1182/Blood.V124.21.1281.1281 |
0.313 |
|
| 2013 |
Towse A, Ossa D, Veenstra D, Carlson J, Garrison L. Understanding the economic value of molecular diagnostic tests: case studies and lessons learned. Journal of Personalized Medicine. 3: 288-305. PMID 25562729 DOI: 10.3390/Jpm3040288 |
0.383 |
|
| 2013 |
Verhoef TI, Redekop WK, Veenstra DL, Thariani R, Beltman PA, van Schie RM, de Boer A, Maitland-van der Zee AH. Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. Pharmacogenomics. 14: 869-83. PMID 23746182 DOI: 10.2217/Pgs.13.74 |
0.341 |
|
| 2013 |
Feero WG, Wicklund C, Veenstra DL. The economics of genomic medicine: insights from the IOM Roundtable on Translating Genomic-Based Research for Health. Jama. 309: 1235-6. PMID 23532238 DOI: 10.1001/Jama.2013.113 |
0.322 |
|
| 2013 |
Calonge N, Fisher NL, Berg AO, Campos-Outcalt D, Djulbegovic B, Ganiats TG, Haddow JE, Klein RD, Lyman DO, Offit K, Pauker SG, Piper M, Richards CS, Strickland OL, Tunis SR, ... Veenstra DL, et al. Recommendations from the EGAPP Working Group: Can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Genetics in Medicine. 15: 517-527. PMID 23429431 DOI: 10.1038/Gim.2012.184 |
0.336 |
|
| 2013 |
Ramsey SD, Barlow WE, Gonzalez-Angulo AM, Tunis S, Baker L, Crowley J, Deverka P, Veenstra D, Hortobagyi GN. Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes. Contemporary Clinical Trials. 34: 1-9. PMID 23000081 DOI: 10.1016/J.Cct.2012.09.003 |
0.315 |
|
| 2013 |
Veenstra DL, Piper M, Haddow JE, Pauker SG, Klein R, Richards CS, Tunis SR, Djulbegovic B, Marrone M, Lin JS, Berg AO, Calonge N. Improving the efficiency and relevance of evidence-based recommendations in the era of whole-genome sequencing: an EGAPP methods update. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 14-24. PMID 22955111 DOI: 10.1038/Gim.2012.106 |
0.322 |
|
| 2013 |
Veenstra DL, Bajaj PS, Carlson JJ, Goertz H. Is erlotinib for first-line use in EGFR+ non-small-cell lung cancer cost-effective? Journal of Clinical Oncology. 31: e19001-e19001. DOI: 10.1200/Jco.2013.31.15_Suppl.E19001 |
0.378 |
|
| 2013 |
McDermott C, Veenstra D, Hansen R, Sullivan S. The Value Of Improving Treatment Adherence In Chronic Hepatitis C Infectio Value in Health. 16: A214. DOI: 10.1016/J.Jval.2013.03.1086 |
0.306 |
|
| 2012 |
Behl AS, Goddard KA, Flottemesch TJ, Veenstra D, Meenan RT, Lin JS, Maciosek MV. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer. Journal of the National Cancer Institute. 104: 1785-95. PMID 23197490 DOI: 10.1093/Jnci/Djs433 |
0.356 |
|
| 2012 |
Wong WB, Ramsey SD, Barlow WE, Garrison LP, Veenstra DL. The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemporary Clinical Trials. 33: 1117-23. PMID 22981891 DOI: 10.1016/J.Cct.2012.08.006 |
0.338 |
|
| 2012 |
Goddard KA, Knaus WA, Whitlock E, Lyman GH, Feigelson HS, Schully SD, Ramsey S, Tunis S, Freedman AN, Khoury MJ, Veenstra DL. Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 14: 633-42. PMID 22516979 DOI: 10.1038/Gim.2012.16 |
0.334 |
|
| 2012 |
Guzauskas GF, Hughes DA, Bradley SM, Veenstra DL. A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention. Clinical Pharmacology and Therapeutics. 91: 829-37. PMID 22453194 DOI: 10.1038/Clpt.2011.303 |
0.336 |
|
| 2012 |
Cheng MM, Ramsey SD, Devine EB, Garrison LP, Bresnahan BW, Veenstra DL. Systematic review of comparative effectiveness data for oncology orphan drugs. The American Journal of Managed Care. 18: 47-62. PMID 22435748 |
0.575 |
|
| 2012 |
Thariani R, Veenstra DL, Carlson JJ, Garrison LP, Ramsey S. Paying for personalized care: cancer biomarkers and comparative effectiveness. Molecular Oncology. 6: 260-6. PMID 22429896 DOI: 10.1016/J.Molonc.2012.02.006 |
0.411 |
|
| 2012 |
Cheng MM, Goulart B, Veenstra DL, Blough DK, Devine EB. A network meta-analysis of therapies for previously untreated chronic lymphocytic leukemia. Cancer Treatment Reviews. 38: 1004-11. PMID 22405931 DOI: 10.1016/J.Ctrv.2012.02.006 |
0.556 |
|
| 2012 |
Babigumira JB, Stergachis A, Veenstra DL, Gardner JS, Ngonzi J, Mukasa-Kivunike P, Garrison LP. Potential cost-effectiveness of universal access to modern contraceptives in Uganda. Plos One. 7: e30735. PMID 22363480 DOI: 10.1371/Journal.Pone.0030735 |
0.368 |
|
| 2012 |
Branch KR, Bresnahan BW, Veenstra DL, Shuman WP, Weintraub WS, Busey JM, Elliott DJ, Mitsumori LM, Strote J, Jobe K, Dubinsky T, Caldwell JH. Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model. Academic Radiology. 19: 265-73. PMID 22209422 DOI: 10.1016/J.Acra.2011.10.029 |
0.341 |
|
| 2012 |
Blondon M, Righini M, Bounameaux H, Veenstra DL. Fondaparinux for isolated superficial vein thrombosis of the legs: a cost-effectiveness analysis. Chest. 141: 321-9. PMID 21757569 DOI: 10.1378/Chest.11-0625 |
0.363 |
|
| 2012 |
Thariani R, Blough DK, Barlow W, Henry NL, Gralow J, Ramsey SD, Veenstra DL. Evaluating the impact of a trial in breast cancer tumor markers: A value of research analysis. Journal of Clinical Oncology. 30: e16524-e16524. DOI: 10.1200/Jco.2012.30.15_Suppl.E16524 |
0.318 |
|
| 2011 |
Thariani R, Carlson JJ, Steuten L, Henry L, Gralow J, Ramsey S, Basu A, Veenstra DL. Evaluating a proposed swog trial of breast cancer tumor markers: A value of research and biobank analysis Medical Decision Making. 32. PMID 28071309 DOI: 10.1177/0272989X12439390 |
0.328 |
|
| 2011 |
Ramsey SD, Veenstra D, Tunis SR, Garrison L, Crowley JJ, Baker LH. How comparative effectiveness research can help advance 'personalized medicine' in cancer treatment. Health Affairs (Project Hope). 30: 2259-68. PMID 22147853 DOI: 10.1377/Hlthaff.2010.0637 |
0.354 |
|
| 2011 |
Babigumira JB, Stergachis A, Veenstra DL, Gardner JS, Ngonzi J, Mukasa-Kivunike P, Garrison LP. Estimating the costs of induced abortion in Uganda: a model-based analysis. Bmc Public Health. 11: 904. PMID 22145859 DOI: 10.1186/1471-2458-11-904 |
0.39 |
|
| 2011 |
Beitelshees AL, Veenstra DL. Evolving research and stakeholder perspectives on pharmacogenomics. Jama. 306: 1252-3. PMID 21934059 DOI: 10.1001/Jama.2011.1343 |
0.336 |
|
| 2011 |
Garrison LP, Bauch CT, Bresnahan BW, Hazlet TK, Kadiyala S, Veenstra DL. Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination. The Journal of Infectious Diseases. 204: S124-32. PMID 21666153 DOI: 10.1093/Infdis/Jir114 |
0.36 |
|
| 2011 |
Cross JT, Veenstra DL, Gardner JS, Garrison LP. Can modeling of health outcomes facilitate regulatory decision making? The benefit-risk tradeoff for rosiglitazone in 1999 vs. 2007. Clinical Pharmacology and Therapeutics. 89: 429-36. PMID 21289618 DOI: 10.1038/Clpt.2010.350 |
0.317 |
|
| 2011 |
Roth JA, Garrison LP, Burke W, Ramsey SD, Carlson R, Veenstra DL. Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics. 14: 59-67. PMID 20407215 DOI: 10.1159/000290452 |
0.37 |
|
| 2010 |
Giovanni MA, Fickie MR, Lehmann LS, Green RC, Meckley LM, Veenstra D, Murray MF. Health-care referrals from direct-to-consumer genetic testing. Genetic Testing and Molecular Biomarkers. 14: 817-9. PMID 20979566 DOI: 10.1089/Gtmb.2010.0051 |
0.687 |
|
| 2010 |
Wong WB, Carlson JJ, Thariani R, Veenstra DL. Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics. 28: 1001-13. PMID 20936884 DOI: 10.2165/11537410-000000000-00000 |
0.433 |
|
| 2010 |
Veenstra DL, Roth JA, Garrison LP, Ramsey SD, Burke W. A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 12: 686-93. PMID 20808229 DOI: 10.1097/Gim.0B013E3181Eff533 |
0.367 |
|
| 2010 |
Cheng MM, Alfonso R, Best JH, Garrison LP, Bruhn D, Veenstra DL. The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment. Journal of Medical Economics. 13: 193-202. PMID 20334490 DOI: 10.3111/13696991003757500 |
0.732 |
|
| 2010 |
Conti R, Veenstra DL, Armstrong K, Lesko LJ, Grosse SD. Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 30: 328-40. PMID 20086232 DOI: 10.1177/0272989X09347014 |
0.349 |
|
| 2010 |
Best JH, Garrison LP, Hollingworth W, Ramsey SD, Veenstra DL. Preference values associated with stage III colon cancer and adjuvant chemotherapy. Quality of Life Research : An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 19: 391-400. PMID 20084462 DOI: 10.1007/S11136-010-9589-5 |
0.625 |
|
| 2010 |
Meckley LM, Gudgeon JM, Anderson JL, Williams MS, Veenstra DL. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics. 28: 61-74. PMID 20014877 DOI: 10.2165/11318240-000000000-00000 |
0.701 |
|
| 2010 |
Limdi NA, Veenstra DL. Expectations, validity, and reality in pharmacogenetics. Journal of Clinical Epidemiology. 63: 960-9. PMID 19995676 DOI: 10.1016/J.Jclinepi.2009.09.006 |
0.358 |
|
| 2009 |
Garrison LP, Veenstra DL. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 1118-23. PMID 19624617 DOI: 10.1111/J.1524-4733.2009.00572.X |
0.353 |
|
| 2009 |
Carlson JJ, Kowdley KV, Sullivan SD, Ramsey SD, Veenstra DL. An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis. Journal of Gastroenterology and Hepatology. 24: 786-91. PMID 19457153 DOI: 10.1111/J.1440-1746.2009.05778.X |
0.305 |
|
| 2009 |
Cheng MM, Lu B, Hu SS, Marelli C, Higashi MK, Patel PA, Li J, Veenstra DL. Optimizing CAD diagnosis in China with CT angiography. Journal of Cardiovascular Computed Tomography. 3: 153-8. PMID 19394919 DOI: 10.1016/J.Jcct.2009.03.005 |
0.752 |
|
| 2009 |
Veenstra D, Burke W. Pharmacogenomics and public health. Public Health Genomics. 12: 131-133. PMID 19204414 DOI: 10.1159/000189624 |
0.439 |
|
| 2009 |
Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 12: 20-7. PMID 18647257 DOI: 10.1111/J.1524-4733.2008.00415.X |
0.4 |
|
| 2008 |
Meckley LM, Wittkowsky AK, Rieder MJ, Rettie AE, Veenstra DL. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients Thrombosis and Haemostasis. 100: 229-239. PMID 18690342 DOI: 10.1160/Th07-09-0552 |
0.679 |
|
| 2008 |
Carlson JJ, Veenstra DL, Ramsey SD. Pharmacoeconomic evaluations in the treatment of non-small cell lung cancer. Drugs. 68: 1105-13. PMID 18484801 DOI: 10.2165/00003495-200868080-00007 |
0.428 |
|
| 2008 |
Garrison LP, Carlson RJ, Carlson JJ, Kuszler PC, Meckley LM, Veenstra DL. A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metabolism Reviews. 40: 377-401. PMID 18464050 DOI: 10.1080/03602530801952500 |
0.671 |
|
| 2008 |
Veenstra DL, Sullivan SD, Lai MY, Lee CM, Tsai CM, Patel KK. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 11: 131-8. PMID 18380625 DOI: 10.1111/J.1524-4733.2007.00221.X |
0.31 |
|
| 2008 |
Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Alimentary Pharmacology & Therapeutics. 27: 1240-1252. PMID 18373637 DOI: 10.1111/J.1365-2036.2008.03691.X |
0.32 |
|
| 2008 |
Carlson JJ, Reyes C, Oestreicher N, Lubeck D, Ramsey SD, Veenstra DL. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC) Lung Cancer. 61: 405-415. PMID 18295368 DOI: 10.1016/J.Lungcan.2007.12.023 |
0.688 |
|
| 2008 |
Karuna ST, Thirlby R, Biehl T, Veenstra D. Cost-effectiveness of laparoscopy versus laparotomy for initial surgical evaluation and treatment of potentially resectable hepatic colorectal metastases: a decision analysis. Journal of Surgical Oncology. 97: 396-403. PMID 18270972 DOI: 10.1002/Jso.20964 |
0.344 |
|
| 2008 |
Henrikson NB, Burke W, Veenstra DL. Ancillary risk information and pharmacogenetic tests: Social and policy implications Pharmacogenomics Journal. 8: 85-89. PMID 17486108 DOI: 10.1038/Sj.Tpj.6500457 |
0.309 |
|
| 2008 |
Meckley L, Gudgeon J, Anderson J, Williams M, Veenstra D. PHP72 GENETIC TESTING FOR WARFARIN INITIATION: A COST-EFFECTIVENESS ANALYSIS BASED ON CURRENT EVIDENCE Value in Health. 11: A51. DOI: 10.1016/S1098-3015(10)70170-4 |
0.72 |
|
| 2007 |
Veenstra DL, Harris J, Gibson RL, Rosenfeld M, Burke W, Watts C. Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 9: 695-704. PMID 18073583 DOI: 10.1097/Gim.0B013E318156Dd07 |
0.385 |
|
| 2007 |
Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 25: 963-77. PMID 17960954 DOI: 10.2165/00019053-200725110-00006 |
0.333 |
|
| 2007 |
Sullivan SD, Veenstra DL, Chen PJ, Chang TT, Chuang WL, Tsai C, Patel K. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. Journal of Gastroenterology and Hepatology. 22: 1494-9. PMID 17716353 DOI: 10.1111/J.1440-1746.2006.04539.X |
0.306 |
|
| 2007 |
Veenstra DL, Sullivan SD, Dusheiko GM, Jacobs M, Aledort JE, Lewis G, Patel KK. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. European Journal of Gastroenterology & Hepatology. 19: 631-8. PMID 17625431 DOI: 10.1097/Meg.0B013E3281108079 |
0.323 |
|
| 2007 |
Carlson J, Oestreicher N, Lubeck DP, Ramsey SD, Veenstra DL. Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 25: 7664-7664. DOI: 10.1200/Jco.2007.25.18_Suppl.7664 |
0.701 |
|
| 2007 |
Gudgeon J, Williams M, Anderson J, Meckley L, Veenstra D. PCASE10 SHOULD GENETIC TESTING BE USED TO GUIDE WARFARIN THERAPY? Value in Health. 10: A205-A206. DOI: 10.1016/S1098-3015(10)69150-4 |
0.682 |
|
| 2007 |
Meckley L, Austin M, Garrison L, Veenstra D. PCV56 THE COST-EFFECTIVENESS LANDSCAPE OF GENETIC TESTING WITH WARFARIN THERAPY Value in Health. 10: A53. DOI: 10.1016/S1098-3015(10)68698-6 |
0.722 |
|
| 2006 |
Cohen AL, Veenstra D. Economic analysis of prevaccination serotesting compared with presumptive immunization for polio, diphtheria, and tetanus in internationally adopted and immigrant infants. Pediatrics. 117: 1650-5. PMID 16651319 DOI: 10.1542/Peds.2005-0822 |
0.301 |
|
| 2006 |
Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenetics and Genomics. 16: 139-47. PMID 16424826 DOI: 10.1097/01.Fpc.0000189801.96220.82 |
0.698 |
|
| 2005 |
Carlson JJ, Henrikson NB, Veenstra DL, Ramsey SD. Economic analyses of human genetics services: a systematic review. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 7: 519-23. PMID 16247290 DOI: 10.1097/01.Gim.0000182467.79495.E2 |
0.308 |
|
| 2005 |
Oestreicher N, Ramsey SD, McCune JS, Linden HM, Veenstra DL. The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma. Cancer. 104: 2054-62. PMID 16216002 DOI: 10.1002/Cncr.21464 |
0.647 |
|
| 2005 |
Oestreicher N, Ramsey SD, Linden HM, McCune JS, van't Veer LJ, Burke W, Veenstra DL. Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genetics in Medicine : Official Journal of the American College of Medical Genetics. 7: 380-9. PMID 16024969 DOI: 10.1097/01.Gim.0000170776.31248.75 |
0.649 |
|
| 2005 |
Veenstra DL, Blough DK, Higashi MK, Farin FM, Srinouanprachan S, Rieder MJ, Rettie AE. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clinical Pharmacology and Therapeutics. 77: 353-64. PMID 15900281 DOI: 10.1016/J.Clpt.2005.01.019 |
0.714 |
|
| 2005 |
Davis GE, Schwartz SR, Veenstra DL, Yueh B. Cost comparison of surgery vs organ preservation for laryngeal cancer. Archives of Otolaryngology--Head & Neck Surgery. 131: 21-6. PMID 15655180 DOI: 10.1001/Archotol.131.1.21 |
0.338 |
|
| 2005 |
Ramsey S, Veenstra D, Clarke L, Penson D, Gandhi S, Hirsch M. PCN14 IS COMBINED ANDROGEN BLOCKADE WITH BICALUTAMIDE COST-EFFECTIVE COMPARED WITH COMBINED ANDROGEN BLOCKADE WITH FLUTAMIDE? Value in Health. 8: 347-348. DOI: 10.1016/S1098-3015(10)62920-8 |
0.35 |
|
| 2004 |
Hu KK, Veenstra DL, Lipsky BA, Saint S. Use of maximal sterile barriers during central venous catheter insertion: clinical and economic outcomes. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 39: 1441-5. PMID 15546079 DOI: 10.1086/425309 |
0.326 |
|
| 2004 |
Flowers CR, Veenstra D. The role of cost-effectiveness analysis in the era of pharmacogenomics. Pharmacoeconomics. 22: 481-93. PMID 15217305 DOI: 10.2165/00019053-200422080-00001 |
0.464 |
|
| 2004 |
Maitland-van der Zee AH, Klungel OH, Stricker BH, Veenstra DL, Kastelein JJ, Hofman A, Witteman JC, Leufkens HG, van Duijn CM, de Boer A. Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics. 14: 53-60. PMID 15128051 DOI: 10.1097/00008571-200401000-00006 |
0.377 |
|
| 2004 |
Higashi MK, Veenstra DL, Langley PC. Health economic evaluation of non-melanoma skin cancer and actinic keratosis. Pharmacoeconomics. 22: 83-94. PMID 14731050 DOI: 10.2165/00019053-200422020-00002 |
0.755 |
|
| 2004 |
Meckley L, Veenstra D. SC4 ECONOMIC EVALUATION OF SCREENING FOR THE A-ADDUCIN GENE VARIANT IN HYPERTENSIVE PATIENTS Value in Health. 7: 228-229. DOI: 10.1016/S1098-3015(10)62093-1 |
0.679 |
|
| 2004 |
Oestreicher N, Veenstra D, Linden H, McCune J, Ramsey S. CE3 THE COSTS OF ADJUVANT CHEMOTHERAPY IN EARLY STAGE BREAST CANCER PATIENTS: COMPARISON OF ATTRIBUTABLE COST AND MICROCOSTING APPROACHES Value in Health. 7: 226. DOI: 10.1016/S1098-3015(10)62085-2 |
0.67 |
|
| 2004 |
Salem L, Anaya D, Veenstra D, Sullivan S, Flum D. Timing of elective colectomy for diverticulitis: A modeled decision analysis Journal of the American College of Surgeons. 199: 69. DOI: 10.1016/J.Jamcollsurg.2004.05.148 |
0.381 |
|
| 2003 |
Chaiyakunapruk N, Veenstra DL, Lipsky BA, Sullivan SD, Saint S. Vascular catheter site care: the clinical and economic benefits of chlorhexidine gluconate compared with povidone iodine. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 37: 764-71. PMID 12955636 DOI: 10.1086/377265 |
0.317 |
|
| 2003 |
Higashi MK, Veenstra DL. Managed care in the genomics era: assessing the cost effectiveness of genetic tests. The American Journal of Managed Care. 9: 493-500. PMID 12866628 |
0.732 |
|
| 2003 |
Reed SD, Dillingham PW, Briggs AH, Veenstra DL, Sullivan SD. A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 23: 252-64. PMID 12809323 DOI: 10.1177/0272989X03023003007 |
0.397 |
|
| 2003 |
Phillips KA, Veenstra D, Van Bebber S, Sakowski J. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics. 4: 231-9. PMID 12718713 DOI: 10.1517/Phgs.4.3.231.22691 |
0.397 |
|
| 2003 |
Flum DR, Flowers C, Veenstra DL. A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy. Journal of the American College of Surgeons. 196: 385-93. PMID 12648690 DOI: 10.1016/S1072-7515(02)01806-9 |
0.314 |
|
| 2003 |
Marciante KD, Veenstra DL, Lipsky BA, Saint S. Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. American Journal of Infection Control. 31: 1-8. PMID 12548250 DOI: 10.1067/Mic.2003.35 |
0.346 |
|
| 2002 |
Higashi MK, Veenstra DL, del Aguila M, Hujoel P. The cost-effectiveness of interleukin-1 genetic testing for periodontal disease. Journal of Periodontology. 73: 1474-84. PMID 12546098 DOI: 10.1902/Jop.2002.73.12.1474 |
0.742 |
|
| 2002 |
Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. Jama. 287: 1690-8. PMID 11926893 DOI: 10.1001/Jama.287.13.1690 |
0.717 |
|
| 2002 |
Veenstra DL. The role of pharmacoeconomics in the genomics era Pharmaceutical News. 9: 21-26. |
0.34 |
|
| 2001 |
Devine EB, Kowdley KV, Veenstra DL, Sullivan SD. Management strategies for ribavirin-induced hemolytic anemia in the treatment of hepatitis C: clinical and economic implications. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 4: 376-84. PMID 11705128 DOI: 10.1046/J.1524-4733.2001.45075.X |
0.369 |
|
| 2001 |
Best JH, Veenstra DL, Geppert J. Trends in expenditures for Medicare liver transplant recipients. Liver Transplantation : Official Publication of the American Association For the Study of Liver Diseases and the International Liver Transplantation Society. 7: 858-62. PMID 11679983 DOI: 10.1053/Jlts.2001.27868 |
0.598 |
|
| 2001 |
Marciante KD, Gardner JS, Veenstra DL, Sullivan SD. Modeling the cost and outcomes of pharmacist-prescribed emergency contraception. American Journal of Public Health. 91: 1443-5. PMID 11527778 DOI: 10.2105/Ajph.91.9.1443 |
0.358 |
|
| 2001 |
Lee TA, Sullivan SD, Veenstra DL, Ramsey SD, Steger PJK, Malinverni R, Pleil AM, Williamson T. Economic evaluation of systemic treatments for cytomegalovirus retinitis in patients with AIDS Pharmacoeconomics. 19: 535-550. PMID 11465299 DOI: 10.2165/00019053-200119050-00008 |
0.334 |
|
| 2000 |
Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. Aaps Pharmsci. 2: E29. PMID 11741245 DOI: 10.1208/Ps020329 |
0.767 |
|
| 2000 |
Saint S, Veenstra DL, Sullivan SD, Chenoweth C, Fendrick AM. The potential clinical and economic benefits of silver alloy urinary catheters in preventing urinary tract infection Archives of Internal Medicine. 160: 2670-2675. PMID 10999983 DOI: 10.1001/Archinte.160.17.2670 |
0.36 |
|
| 2000 |
Saint S, Veenstra DL, Lipsky BA. The clinical and economic consequences of nosocomial central venous catheter-related infection: Are antimicrobial catheters useful? Infection Control and Hospital Epidemiology. 21: 375-380. PMID 10879567 DOI: 10.1086/501776 |
0.314 |
|
| 2000 |
Veenstra DL, Higashi MK, Phillips KA. Assessing the comprehensiveness of pharmacogenomics Aaps Pharmsci. 2: 1-11. |
0.766 |
|
| 1999 |
Saint S, Veenstra DL, Sullivan SD. The use of meta-analysis in cost-effectiveness analysis issues and recommendations Pharmacoeconomics. 15: 1-8. PMID 10345156 DOI: 10.2165/00019053-199915010-00001 |
0.36 |
|
| 1999 |
Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and long-term cost of steroid-related side effects after renal transplantation. American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation. 33: 829-39. PMID 10213637 DOI: 10.1016/S0272-6386(99)70414-2 |
0.601 |
|
| 1999 |
Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. Incidence and cost of steroid side effects after renal transplantation. Transplantation Proceedings. 31: 301-2. PMID 10083116 DOI: 10.1016/S0041-1345(98)01635-2 |
0.609 |
|
| 1998 |
Veenstra DL, Best JH, Hornberger J, Sullivan SD, Hricik DE. THE INCIDENCE AND COSTS OF STEROID-RELATED SIDE EFFECTS IN RENAL TRANSPLANTATION Transplantation. 65: 132. DOI: 10.1097/00007890-199805131-00214 |
0.61 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2008 |
Spackman DE, Veenstra DL. A cost-effectiveness analysis of currently approved treatments for HBeAg-positive chronic hepatitis B. Pharmacoeconomics. 26: 937-49. PMID 18850763 DOI: 10.2165/00019053-200826110-00006 |
0.3 |
|
| 2014 |
Boudreau DM, Guzauskas GF, Chen E, Lalla D, Tayama D, Fagan SC, Veenstra DL. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence. Stroke; a Journal of Cerebral Circulation. 45: 3032-9. PMID 25190439 DOI: 10.1161/Strokeaha.114.005852 |
0.3 |
|
| 2012 |
Thariani R, Wong W, Carlson JJ, Garrison L, Ramsey S, Deverka PA, Esmail L, Rangarao S, Hoban CJ, Baker LH, Veenstra DL. Prioritization in comparative effectiveness research: the CANCERGEN Experience. Medical Care. 50: 388-93. PMID 22274803 DOI: 10.1097/Mlr.0B013E3182422A3B |
0.299 |
|
| 2013 |
Roth J, Boudreau D, Fujii M, Farin F, Rettie A, Thummel K, Veenstra D. PS3-4: Genetic Risk Factors for Major Bleeding in Warfarin Patients in a Community Setting Clinical Medicine & Research. 11: 148-148. DOI: 10.3121/Cmr.2013.1176.Ps3-4 |
0.298 |
|
| 2005 |
Veenstra DL, Iloeje UH, Sullivan SD, Tafesse E, Cross A, Di Bisceglie A, Kowdley K, Gish RG. Cost-Effectiveness of Entecavir vs. Lamivudine with Adefovir Salvage as First-Line Treatment in HBeAg-Positive Chronic Hepatitis B American Journal of Gastroenterology. 100: S278-S279. DOI: 10.14309/00000434-200509001-00748 |
0.296 |
|
| 2019 |
Carlson JJ, Walton SM, Basu A, Chapman RH, Campbell JD, McQueen RB, Pearson SD, Touchette DR, Veenstra D, Whittington MD, Ollendorf DA. Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States. Pharmacoeconomics. PMID 31485925 DOI: 10.1007/S40273-019-00832-2 |
0.295 |
|
| 2011 |
Ramsey SD, Barlow WE, Moinpour C, Gonzalez-Angulo AM, Hortobagyi GN, Veenstra DL, Garrison LP, Tunis SR, Baker LH. Incorporating comparative effectiveness research study endpoints into the treatment for positive-node, endocrine-responsive breast cancer (RxPONDER) study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS101. PMID 28022861 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps101 |
0.295 |
|
| 2003 |
Patel KK, Veenstra DL, Patrick DL. A review of selected patient-generated outcome measures and their application in clinical trials. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 6: 595-603. PMID 14627066 DOI: 10.1046/J.1524-4733.2003.65236.X |
0.293 |
|
| 2020 |
Hendrix N, Regier DA, Chatterjee J, Dhanda DS, Basu A, Veenstra DL, Carlson JJ. Provider preferences for resolving uncertainty and avoiding harms in precision medicine: a discrete choice experiment. Personalized Medicine. PMID 32804043 DOI: 10.2217/Pme-2020-0018 |
0.293 |
|
| 2013 |
Bajaj PS, Veenstra DL. A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 374-81. PMID 23138100 DOI: 10.1038/Gim.2012.139 |
0.293 |
|
| 2013 |
Bennette CS, Trinidad SB, Fullerton SM, Patrick D, Amendola L, Burke W, Hisama FM, Jarvik GP, Regier DA, Veenstra DL. Return of incidental findings in genomic medicine: measuring what patients value--development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 873-81. PMID 23722871 DOI: 10.1038/Gim.2013.63 |
0.293 |
|
| 2020 |
Hendrix N, Hauber AB, Lee CI, Bansal A, Veenstra DL. Provider preferences for attributes of artificial intelligence in breast cancer screening: A discrete choice experiment. Journal of Clinical Oncology. 38: e14118-e14118. DOI: 10.1200/Jco.2020.38.15_Suppl.E14118 |
0.291 |
|
| 2014 |
Calonge N, Klein RD, Berg AO, Berg JS, Armstrong K, Botkin J, Campos-Outcalt D, Djulbegovic B, Fisher NL, Ganiats TG, Haddow JE, Hayes M, Janssens ACJW, Kaye C, Lyman DO, ... ... Veenstra DL, et al. The EGAPP initiative: Lessons learned Genetics in Medicine. 16: 217-224. PMID 23928914 DOI: 10.1038/Gim.2013.110 |
0.291 |
|
| 2017 |
Manolio TA, Hutter CM, Avigan M, Cibotti R, Davis RL, Denny JC, Grenade L, Wheatley LM, Carrington MN, Chantratita W, Chung WH, Dalton AD, Hung SI, Lee MTM, Leeder JS, ... ... Veenstra D, et al. Research Directions in Genetic Predispositions to Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis. Clinical Pharmacology and Therapeutics. PMID 29105735 DOI: 10.1002/Cpt.890 |
0.291 |
|
| 2003 |
Rulyak SJ, Kimmey MB, Veenstra DL, Brentnall TA. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointestinal Endoscopy. 57: 23-9. PMID 12518126 DOI: 10.1067/Mge.2003.28 |
0.291 |
|
| 2019 |
Robinson JO, Wynn J, Biesecker B, Biesecker LG, Bernhardt B, Brothers KB, Chung WK, Christensen KD, Green RC, McGuire AL, Hart MR, Griesemer I, Patrick DL, Rini C, Veenstra D, et al. Psychological outcomes related to exome and genome sequencing result disclosure: a meta-analysis of seven Clinical Sequencing Exploratory Research (CSER) Consortium studies. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 31189963 DOI: 10.1038/S41436-019-0565-3 |
0.29 |
|
| 2011 |
Woods B, Veenstra D, Hawkins N. Prioritizing pharmacogenetic research: a value of information analysis of CYP2D6 testing to guide breast cancer treatment. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 14: 989-1001. PMID 22152167 DOI: 10.1016/J.Jval.2011.05.048 |
0.29 |
|
| 2020 |
Pagán JA, Brown HS, Rowe J, Schneider JE, Veenstra DL, Gupta A, Berger SM, Chung WK, Appelbaum PS. Genetic Variant Reinterpretation: Economic and Population Health Management Challenges. Population Health Management. PMID 32905743 DOI: 10.1089/Pop.2020.0115 |
0.289 |
|
| 2020 |
Hao J, Chen N, Hassen D, Klinger T, Betts M, Hartzel D, Veenstra D, Spencer S, Williams M, Snyder S, Petersan J, Schlieder V, Woods L, Jones L. Providers Prescribing Behavior for Lipid-lowering Therapy after Receiving Patients Positive Genetic Test for Familial Hypercholesterolemia† Journal of Clinical Lipidology. 14: 572-573. DOI: 10.1016/J.Jacl.2020.05.049 |
0.289 |
|
| 2017 |
Laurino MY, Truitt AR, Tenney L, Fisher D, Lindor NM, Veenstra D, Jarvik GP, Newcomb PA, Fullerton SM. Clinical verification of genetic results returned to research participants: findings from a Colon Cancer Family Registry. Molecular Genetics & Genomic Medicine. 5: 700-708. PMID 29178651 DOI: 10.1002/Mgg3.328 |
0.288 |
|
| 2010 |
Overby CL, Tarczy-Hornoch P, Hoath JI, Kalet IJ, Veenstra DL. Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support. Bmc Bioinformatics. 11: S10. PMID 21044357 DOI: 10.1186/1471-2105-11-S9-S10 |
0.287 |
|
| 2012 |
Deverka PA, Lavallee DC, Desai PJ, Armstrong J, Gorman M, Hole-Curry L, O'Leary J, Ruffner BW, Watkins J, Veenstra DL, Baker LH, Unger JM, Ramsey SD. Facilitating comparative effectiveness research in cancer genomics: evaluating stakeholder perceptions of the engagement process. Journal of Comparative Effectiveness Research. 1: 359-70. PMID 23459832 DOI: 10.2217/Cer.12.36 |
0.285 |
|
| 2013 |
Thariani R, Henry NL, Ramsey SD, Blough DK, Barlow B, Gralow JR, Veenstra DL. Is a comparative clinical trial for breast cancer tumor markers to monitor disease recurrence warranted? A value of information analysis. Journal of Comparative Effectiveness Research. 2: 325-34. PMID 24236631 DOI: 10.2217/Cer.13.15 |
0.285 |
|
| 2010 |
Guzauskas G, Veenstra D, Hughes D. PCV21 A BENEFIT-RISK ASSESSMENT OF USING CYP2C19 GENOTYPE INFORMATION TO GUIDE ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME Value in Health. 13: A152-A153. DOI: 10.1016/S1098-3015(10)72741-8 |
0.284 |
|
| 2005 |
Veenstra D, Sullivan S, Lewis G. PGI5 COST-EFFECTIVENESS OF PEGINTERFERON ALFA-2A (40KD) COMPARED TO LAMIVUDINE FOR THE TREATMENT OF E ANTIGEN NEGATIVE CHRONIC HEPATITIS B IN THE UK Value in Health. 8: 371. DOI: 10.1016/S1098-3015(10)62994-4 |
0.284 |
|
| 2012 |
Deverka PA, Lavallee DC, Desai PJ, Esmail LC, Ramsey SD, Veenstra DL, Tunis SR. Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. Journal of Comparative Effectiveness Research. 1: 181-194. PMID 22707880 DOI: 10.2217/Cer.12.7 |
0.283 |
|
| 2013 |
Guzauskas GF, Garrison LP, Stock J, Au S, Doyle DL, Veenstra DL. Stakeholder perspectives on decision-analytic modeling frameworks to assess genetic services policy. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 84-7. PMID 22836698 DOI: 10.1038/Gim.2012.92 |
0.283 |
|
| 2004 |
Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. Journal of Clinical Gastroenterology. 38: S144-7. PMID 15602162 DOI: 10.1097/00004836-200411003-00005 |
0.283 |
|
| 2019 |
Kim DD, Guzauskas GF, Bennette CS, Basu A, Veenstra DL, Ramsey SD, Carlson JJ. Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment. Pharmacoeconomics. PMID 31631254 DOI: 10.1007/S40273-019-00848-8 |
0.283 |
|
| 2011 |
Roth JA, Carlson JJ, Steuten L, Ramsey SD, Veenstra DL. The value of research for ERCC1 testing in stage I non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e16544. PMID 28022039 DOI: 10.1200/Jco.2011.29.15_Suppl.E16544 |
0.282 |
|
| 2012 |
Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141: e152S-84S. PMID 22315259 DOI: 10.1378/Chest.11-2295 |
0.282 |
|
| 2018 |
Williams JL, Chung WK, Fedotov A, Kiryluk K, Weng C, Connolly JJ, Harr M, Hakonarson H, Leppig KA, Larson EB, Jarvik GP, Veenstra DL, Hoell C, Smith ME, Holm IA, et al. Harmonizing Outcomes for Genomic Medicine: Comparison of eMERGE Outcomes to ClinGen Outcome/Intervention Pairs. Healthcare (Basel, Switzerland). 6. PMID 30011878 DOI: 10.3390/Healthcare6030083 |
0.281 |
|
| 2009 |
Bradley SM, Levy WC, Veenstra DL. Cost-consequences of ultrafiltration for acute heart failure: a decision model analysis. Circulation. Cardiovascular Quality and Outcomes. 2: 566-73. PMID 20031894 DOI: 10.1161/Circoutcomes.109.853556 |
0.28 |
|
| 2020 |
Makhnoon S, Bowen DJ, Shirts BH, Fullerton SM, Meischke HW, Larson EB, Ralston JD, Leppig K, Crosslin DR, Veenstra D, Jarvik GP. Relationship between genetic knowledge and familial communication of CRC risk and intent to communicate CRCP genetic information: insights from FamilyTalk eMERGE III. Translational Behavioral Medicine. PMID 32579152 DOI: 10.1093/Tbm/Ibaa054 |
0.28 |
|
| 2004 |
Phillips KA, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. The American Journal of Managed Care. 10: 425-32. PMID 15298364 |
0.279 |
|
| 2019 |
Regier DA, Veenstra DL, Basu A, Carlson JJ. Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study. Pharmacoeconomics. PMID 31489595 DOI: 10.1007/S40273-019-00834-0 |
0.279 |
|
| 2009 |
Salinger DH, Shen DD, Thummel K, Wittkowsky AK, Vicini P, Veenstra DL. Pharmacogenomic trial design: use of a PK/PD model to explore warfarin dosing interventions through clinical trial simulation. Pharmacogenetics and Genomics. 19: 965-71. PMID 19881396 DOI: 10.1097/Fpc.0B013E3283333B80 |
0.278 |
|
| 2015 |
Regier DA, Peacock SJ, Pataky R, van der Hoek K, Jarvik GP, Hoch J, Veenstra D. Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment. Cmaj : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne. 187: E190-7. PMID 25754703 DOI: 10.1503/Cmaj.140697 |
0.278 |
|
| 2012 |
Faulkner E, Annemans L, Garrison L, Helfand M, Holtorf AP, Hornberger J, Hughes D, Li T, Malone D, Payne K, Siebert U, Towse A, Veenstra D, Watkins J. Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 15: 1162-71. PMID 23244820 DOI: 10.1016/J.Jval.2012.05.006 |
0.278 |
|
| 2004 |
Hu KK, Lipsky BA, Veenstra DL, Saint S. Using maximal sterile barriers to prevent central venous catheter-related infection: a systematic evidence-based review. American Journal of Infection Control. 32: 142-6. PMID 15153925 DOI: 10.1016/J.Ajic.2003.10.006 |
0.278 |
|
| 2002 |
Klungel OH, Heckbert SR, de Boer A, Leufkens HG, Sullivan SD, Fishman PA, Veenstra DL, Psaty BM. Lipid-lowering drug use and cardiovascular events after myocardial infarction. The Annals of Pharmacotherapy. 36: 751-7. PMID 11978147 DOI: 10.1345/Aph.1A308 |
0.277 |
|
| 2015 |
Roth JA, Bradley K, Thummel KE, Veenstra DL, Boudreau D. Alcohol misuse, genetics, and major bleeding among warfarin therapy patients in a community setting. Pharmacoepidemiology and Drug Safety. 24: 619-27. PMID 25858232 DOI: 10.1002/Pds.3769 |
0.277 |
|
| 2016 |
Hart R, Veenstra DL, Boudreau DM, Roth JA. The Impact of Body Mass Index and Genetics on Warfarin Major Bleeding Outcomes in a Community Setting. The American Journal of Medicine. PMID 27593608 DOI: 10.1016/J.Amjmed.2016.08.017 |
0.276 |
|
| 2020 |
Jones L, Chen N, Hassen D, Klinger T, McMinn M, Hartzel D, Veenstra D, Spencer S, Snyder S, Peterson J, Schlieder V, Williams M, Hao J, Woods L, Garbett S, et al. Disclosure of s Genetic Risk Variant to Familial Hypercholesterolemia Improves Adherence to Lipid Lowering Therapy Journal of Clinical Lipidology. 14: 563-564. DOI: 10.1016/J.Jacl.2020.05.034 |
0.276 |
|
| 2014 |
Bajaj PS, Veenstra DL, Goertz HP, Carlson JJ. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis. Journal of Medical Economics. 17: 538-46. PMID 24716717 DOI: 10.3111/13696998.2014.912987 |
0.275 |
|
| 2012 |
Guzauskas GF, Boudreau DM, Villa KF, Levine SR, Veenstra DL. The cost-effectiveness of primary stroke centers for acute stroke care. Stroke; a Journal of Cerebral Circulation. 43: 1617-23. PMID 22535277 DOI: 10.1161/Strokeaha.111.648238 |
0.272 |
|
| 2013 |
Carlson JJ, Thariani R, Roth J, Gralow J, Henry NL, Esmail L, Deverka P, Ramsey SD, Baker L, Veenstra DL. Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 33: 463-71. PMID 23635833 DOI: 10.1177/0272989X13484388 |
0.272 |
|
| 2016 |
Veenstra DL, Guzauskas GF, Villa KF, Boudreau DM. The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant. Journal of Medical Economics. 1-27. PMID 28008770 DOI: 10.1080/13696998.2016.1275652 |
0.272 |
|
| 2005 |
Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M. 28: The Cost-Effectiveness of Combined Androgen Blockade with Bicalutamide and LHRH Agonist in Men with Stage D2 Prostate Cancer Journal of Urology. 173: 8-8. DOI: 10.1016/S0022-5347(18)34293-9 |
0.272 |
|
| 2013 |
Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos A-, Vandvik PO. Recommendations for prophylaxis of pregnancy-related venous thromboembolism in carriers of inherited thrombophilia. Comment on the 2012 ACCP guidelines. Journal of Thrombosis and Haemostasis. 11: 1779-1781. PMID 23789890 DOI: 10.1111/Jth.12330 |
0.271 |
|
| 2003 |
Phillips K, Van Bebber S, Veenstra D, Sakowski J. The Economics of Pharmacogenomics Current Pharmacogenomics. 1: 277-284. DOI: 10.2174/1570160033476197 |
0.27 |
|
| 2002 |
Veenstra DL, Ramsey SD, Sullivan SD. A guideline for the use of pharmacoeconomic models of diabetes treatment in the US managed-care environment. Pharmacoeconomics. 20: 21-30. PMID 12036381 DOI: 10.2165/00019053-200220001-00003 |
0.268 |
|
| 2012 |
Dale CR, Madtes DK, Fan VS, Gorden JA, Veenstra DL. Navigational bronchoscopy with biopsy versus computed tomography-guided biopsy for the diagnosis of a solitary pulmonary nodule: a cost-consequences analysis. Journal of Bronchology & Interventional Pulmonology. 19: 294-303. PMID 23207529 DOI: 10.1097/Lbr.0B013E318272157D |
0.267 |
|
| 2013 |
Esmail LC, Roth J, Rangarao S, Carlson JJ, Thariani R, Ramsey SD, Veenstra DL, Deverka P. Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 15: 115-22. PMID 23037935 DOI: 10.1038/Gim.2012.103 |
0.267 |
|
| 2011 |
Bloudek LM, Spackman DE, Veenstra DL, Sullivan SD. CDR state transition probabilities in Alzheimer's disease with and without cholinesterase inhibitor intervention in an observational cohort. Journal of Alzheimer's Disease : Jad. 24: 599-607. PMID 21297268 DOI: 10.3233/Jad-2011-101758 |
0.266 |
|
| 2003 |
Lee T, Veenstra D, Iloeje U, Sullivan S. PIN34: DIRECT MEDICAL COSTS ASSOCIATED WITH HEPATITIS B VIRUS (HBV) INFECTION IN THE UNITED STATES Value in Health. 6: 263-264. DOI: 10.1016/S1098-3015(10)64011-9 |
0.266 |
|
| 2013 |
Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Annals of Emergency Medicine. 61: 46-55. PMID 22633340 DOI: 10.1016/J.Annemergmed.2012.04.020 |
0.265 |
|
| 2016 |
Green RC, Goddard KA, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, ... ... Veenstra DL, et al. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. American Journal of Human Genetics. 99: 246. PMID 27392080 DOI: 10.1016/J.Ajhg.2016.06.002 |
0.265 |
|
| 2018 |
Guzauskas GF, Masaquel A, Reyes C, Bernaards C, Krivasi T, Veenstra DL. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US. Journal of Medical Economics. 1-18. PMID 29898619 DOI: 10.1080/13696998.2018.1489254 |
0.264 |
|
| 2011 |
Carlson JJ, Wong WB, Veenstra DL, Reyes C. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer. Journal of Medical Economics. 14: 159-66. PMID 21288059 DOI: 10.3111/13696998.2011.557457 |
0.264 |
|
| 2017 |
Guzauskas GF, Chen E, Lalla D, Yu E, Tayama D, Veenstra DL. What is the value of conducting a trial of r-tPA for the treatment of mild stroke patients? International Journal of Stroke : Official Journal of the International Stroke Society. 12: 137-144. PMID 28134053 DOI: 10.1177/1747493016669887 |
0.263 |
|
| 2018 |
Basu A, Veenstra DL, Carlson JJ, Wang WJ, Branch K, Probstfield J. How can clinical researchers quantify the value of their proposed comparative research? American Heart Journal. PMID 30638543 DOI: 10.1016/J.Ahj.2018.12.003 |
0.261 |
|
| 2009 |
Carlson JJ, Garrison LP, Ramsey SD, Veenstra DL. Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis. Journal of Cancer Research and Clinical Oncology. 135: 1483-93. PMID 19430813 DOI: 10.1007/S00432-009-0595-3 |
0.259 |
|
| 2007 |
Veenstra DL. The cost-effectiveness of warfarin pharmacogenomics [2] Journal of Thrombosis and Haemostasis. 5: 1974-1975. PMID 17650084 DOI: 10.1111/j.1538-7836.2007.02699.x |
0.258 |
|
| 2020 |
Guzauskas G, Garbett S, Zhou Z, Spencer S, Smith H, Hao J, Snyder S, Graves J, Peterson J, Williams M, Veenstra D. PCN176 HOW MUCH VALUE DOES CASCADE TESTING OF FIRST-DEGREE RELATIVES ADD TO POPULATION SCREENING FOR HEREDITARY BREAST AND OVARIAN CANCER? Value in Health. 23: S54. DOI: 10.1016/J.Jval.2020.04.1657 |
0.258 |
|
| 2006 |
Van Der Palen J, Monninkhof E, Van Der Valk P, Sullivan SD, Veenstra DL. Cost effectiveness of inhaled steroid withdrawal in outpatients with chronic obstructive pulmonary disease Thorax. 61: 29-33. PMID 16244087 DOI: 10.1136/thx.2005.044578 |
0.257 |
|
| 2008 |
Flockhart DA, O'Kane D, Williams MS, Watson MS, Flockhart DA, Gage B, Gandolfi R, King R, Lyon E, Nussbaum R, O'Kane D, Schulman K, Veenstra D, Williams MS, Watson MS, et al. Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarin. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 10: 139-50. PMID 18281922 DOI: 10.1097/Gim.0B013E318163C35F |
0.257 |
|
| 2018 |
Williams JK, Feero WG, Veenstra DL, Starkweather A, Cashion AK. Considerations in initiating genomic screening programs in health care systems. Nursing Outlook. PMID 30093136 DOI: 10.1016/J.Outlook.2018.06.008 |
0.257 |
|
| 2012 |
Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 141: e691S-736S. PMID 22315276 DOI: 10.1378/Chest.11-2300 |
0.257 |
|
| 2009 |
Veenstra DL, Garrison LP, Ramsey SD. CHAPTER 36 – Economic Issues and Genomic Medicine Genomic and Personalized Medicinevolumes I & Ii. 424-433. DOI: 10.1016/B978-0-12-369420-1.00036-6 |
0.255 |
|
| 2008 |
Jaja C, Burke W, Thummel K, Edwards K, Veenstra DL. Cytochrome p450 enzyme polymorphism frequency in indigenous and native american populations: a systematic review. Community Genetics. 11: 141-9. PMID 18376110 DOI: 10.1159/000113876 |
0.255 |
|
| 2015 |
Basu A, Carlson JJ, Veenstra DL. A Framework for Prioritizing Research Investments in Precision Medicine. Medical Decision Making : An International Journal of the Society For Medical Decision Making. PMID 26502985 DOI: 10.1016/J.Jval.2015.09.2777 |
0.254 |
|
| 2016 |
Guzauskas GF, Villa KF, Vanhove GF, Fisher VL, Veenstra DL. Risk-Benefit Analysis of Pediatric-Inspired Versus Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Protocols for Acute Lymphoblastic Leukemia in Adolescents and Young Adults. Journal of Adolescent and Young Adult Oncology. PMID 27779442 DOI: 10.1089/Jayao.2016.0049 |
0.25 |
|
| 2021 |
Spencer SJ, Guzauskas GF, FeLizzi F, Launonen A, Dawson K, Veenstra DL, Masaquel A. Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma. Journal of Managed Care & Specialty Pharmacy. 1-10. PMID 33586513 DOI: 10.18553/jmcp.2021.20424 |
0.249 |
|
| 2003 |
Gray DT, Veenstra DL. Comparative economic analyses of minimally invasive direct coronary artery bypass surgery. The Journal of Thoracic and Cardiovascular Surgery. 125: 618-24. PMID 12658204 DOI: 10.1067/Mtc.2003.14 |
0.249 |
|
| 2018 |
Feero WG, Wicklund CA, Veenstra D. Precision Medicine, Genome Sequencing, and Improved Population Health. Jama. 319: 1979-1980. PMID 29547675 DOI: 10.1001/Jama.2018.2925 |
0.248 |
|
| 2015 |
Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting low accrual in the Clinical Trials Cooperative Group Program’s phase II/III oncology trials. Journal of Clinical Oncology. 33: 6522-6522. DOI: 10.1200/Jco.2015.33.15_Suppl.6522 |
0.248 |
|
| 2014 |
Gray SW, Martins Y, Feuerman LZ, Bernhardt BA, Biesecker BB, Christensen KD, Joffe S, Rini C, Veenstra D, McGuire AL. Social and behavioral research in genomic sequencing: approaches from the Clinical Sequencing Exploratory Research Consortium Outcomes and Measures Working Group. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 16: 727-35. PMID 24625446 DOI: 10.1038/Gim.2014.26 |
0.245 |
|
| 2019 |
Henderson LM, Robinson RF, Ray L, Li T, Dillard DA, Schilling BD, Mosley M, Janssen PL, Fohner AE, Rettie AE, Thummel KE, Thornton TA, Veenstra DL. VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People. Clinical and Translational Science. PMID 30821933 DOI: 10.1111/Cts.12611 |
0.244 |
|
| 2004 |
Veenstra DL. Bringing genomics to the bedside: a cost-effective pharmacogenomic test? Pharmacogenetics. 14: 333-4. PMID 15247624 DOI: 10.1097/00008571-200406000-00001 |
0.243 |
|
| 2003 |
Rettie AE, Tai G, Veenstra DL, Farin FM, Srinouanprachan S, Lin YS, Thummel KE, Hines RN. CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians. Blood. 101: 2896-7. PMID 12642346 DOI: 10.1182/Blood-2002-11-3452 |
0.242 |
|
| 1999 |
Saint S, Veenstra D, Sullivan S, Chenoweth C, Fendrick A. The clinical and economic effects of silver alloy urinary catheters to prevent urinary tract infection American Journal of Infection Control. 27: 186. DOI: 10.1016/S0196-6553(99)80029-7 |
0.241 |
|
| 2020 |
Basit A, Prasad B, Estergreen JK, Sabath DE, Alade N, Veenstra D, Rettie AE, Thummel K. A novel LC-MS/MS assay for quantification of des-carboxy prothrombin and characterization of warfarin induced changes. Clinical and Translational Science. PMID 32004415 DOI: 10.1111/Cts.12757 |
0.241 |
|
| 2007 |
Veenstra D, Salinger P, Garrison L, Shen D, Vicini P. Phm16 Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic (P3) Modeling To Inform Pharmacogenomic Trial Design And Risk Management Value in Health. 10. DOI: 10.1016/S1098-3015(10)65043-7 |
0.24 |
|
| 2004 |
Salem L, Veenstra DL, Sullivan SD, Flum DR. The timing of elective colectomy in diverticulitis: a decision analysis. Journal of the American College of Surgeons. 199: 904-12. PMID 15555974 DOI: 10.1016/j.jamcollsurg.2004.07.029 |
0.239 |
|
| 2020 |
Hendrix N, Marcum ZA, Veenstra DL. Medication persistence of targeted immunomodulators for plaque psoriasis: A retrospective analysis using an U.S. claims database. Pharmacoepidemiology and Drug Safety. PMID 32364664 DOI: 10.1002/Pds.5021 |
0.239 |
|
| 2013 |
Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. The validity of dependence as a health outcome measure in Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 28: 245-52. PMID 23512996 DOI: 10.1177/1533317513481092 |
0.237 |
|
| 2003 |
Ginocchio RH, Veenstra DL, Connell FA, Marrazzo JM. The clinical and economic consequences of screening young men for genital chlamydial infection. Sexually Transmitted Diseases. 30: 99-106. PMID 12567164 DOI: 10.1097/00007435-200302000-00001 |
0.237 |
|
| 2017 |
Gaskill CE, Kling CE, Varghese TK, Veenstra DL, Thirlby RC, Flum DR, Alfonso-Cristancho R. Financial benefit of a smoking cessation program prior to elective colorectal surgery. The Journal of Surgical Research. 215: 183-189. PMID 28688645 DOI: 10.1016/J.Jss.2017.03.067 |
0.236 |
|
| 2019 |
Bounthavong M, Suh K, Christopher MLD, Veenstra DL, Basu A, Devine EB. Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment. Research in Social & Administrative Pharmacy : Rsap. PMID 31706950 DOI: 10.1016/J.Sapharm.2019.10.015 |
0.236 |
|
| 2021 |
Lee W, Dayer V, Jiao B, Carlson JJ, Devine B, Veenstra DL. Use of real-world evidence in economic assessments of pharmaceuticals in the United States. Journal of Managed Care & Specialty Pharmacy. 27: 5-14. PMID 33377439 DOI: 10.18553/jmcp.2021.27.1.005 |
0.234 |
|
| 2021 |
Beal B, Shih V, Campbell J, Veenstra D, Devine B. Comparing Healthcare Resource Utilization and Costs for Patients with Normal Tension Glaucoma Across Levels of Severity: A Retrospective Cohort Study. Clinical Ophthalmology (Auckland, N.Z.). 15: 453-460. PMID 33603322 DOI: 10.2147/OPTH.S284474 |
0.234 |
|
| 2012 |
Spackman DE, Kadiyala S, Neumann PJ, Veenstra DL, Sullivan SD. Measuring Alzheimer disease progression with transition probabilities: estimates from NACC-UDS. Current Alzheimer Research. 9: 1050-8. PMID 22175655 DOI: 10.2174/156720512803569046 |
0.233 |
|
| 2002 |
Sullivan SD, Lew DP, Devine EB, Hakim Z, Reiber GE, Veenstra DL. Health state preference assessment in diabetic peripheral neuropathy. Pharmacoeconomics. 20: 1079-89. PMID 12456202 DOI: 10.2165/00019053-200220150-00004 |
0.232 |
|
| 1999 |
Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection Journal of the American Medical Association. 282: 554-560. PMID 10450717 DOI: 10.1001/jama.282.6.554 |
0.231 |
|
| 2020 |
Ferket BS, Veenstra DL. Economic value of exome sequencing for suspected monogenic disorders. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 32601385 DOI: 10.1038/S41436-020-0888-0 |
0.23 |
|
| 2019 |
Bounthavong M, Devine EB, Christopher MLD, Harvey MA, Veenstra DL, Basu A. Implementation evaluation of academic detailing on naloxone prescribing trends at the United States Veterans Health Administration. Health Services Research. PMID 31313839 DOI: 10.1111/1475-6773.13194 |
0.226 |
|
| 2022 |
Jiang S, Mathias PC, Hendrix N, Shirts BH, Tarczy-Hornoch P, Veenstra D, Malone D, Devine B. Implementation of pharmacogenomic clinical decision support for health systems: a cost-utility analysis. The Pharmacogenomics Journal. PMID 35365779 DOI: 10.1038/s41397-022-00275-7 |
0.226 |
|
| 2023 |
Appelbaum PS, Berger SM, Brokamp E, Brown HS, Burke W, Clayton EW, Evans BJ, Hamid R, Marchant GE, Martin DM, O'Connor BC, Pagán JA, Parens E, Roberts JL, Rowe J, ... ... Veenstra DL, et al. Practical Considerations for Reinterpretation of Individual Genetic Variants. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 100801. PMID 36748709 DOI: 10.1016/j.gim.2023.100801 |
0.225 |
|
| 2008 |
Cheng M, Hu S, Lu B, Higashi M, Marelli C, Li J, Veenstra D. PCV43 OPTIMIZATION OF DIAGNOSIS AND TREATMENT OF CORONARY ARTERY DISEASE IN CHINA WITH USE OF CORONARY CT ANGIOGRAPHY Value in Health. 11: A199. DOI: 10.1016/S1098-3015(10)70631-8 |
0.221 |
|
| 2008 |
Limdi NA, Veenstra DL. Warfarin pharmacogenetics. Pharmacotherapy. 28: 1084-97. PMID 18752379 DOI: 10.1592/phco.28.9.1084 |
0.221 |
|
| 2022 |
Ferket BS, Baldwin Z, Murali P, Pai A, Mittendorf KF, Russell HV, Chen F, Lynch FL, Lich KH, Hindorff LA, Savich R, Slavotinek A, Smith HS, Gelb BD, Veenstra DL. Cost-effectiveness frameworks for comparing genome and exome sequencing versus conventional diagnostic pathways: A scoping review and recommended methods. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 35833928 DOI: 10.1016/j.gim.2022.06.004 |
0.217 |
|
| 2003 |
Veenstra D, Sullivan S, Iloeje U. PIN35: ESTIMATING FUTURE HEPATITIS B VIRUS (HBV) DISEASE BURDEN IN THE UNITED STATES USING A DISEASE SIMULATION MODEL Value in Health. 6: 264. DOI: 10.1016/S1098-3015(10)64012-0 |
0.216 |
|
| 2008 |
Strassels SA, Blough DK, Veenstra DL, Hazlet TK, Sullivan SD. Clinical and demographic characteristics help explain variations in pain at the end of life. Journal of Pain and Symptom Management. 35: 10-9. PMID 17959344 DOI: 10.1016/J.Jpainsymman.2007.02.036 |
0.216 |
|
| 2001 |
Malone DC, Sullivan SD, Veenstra DL. Determining unit cost values for health care resources in pharmacoeconomic studies Formulary. 36: 294-304. |
0.215 |
|
| 2000 |
Devine E, Sullivan S, Lew D, Veenstra D. ICP4: HEALTH STATE PREFERENCES IN DIABETIC PERIPHERAL NEUROPATHY Value in Health. 3: 56. DOI: 10.1016/S1098-3015(11)70337-0 |
0.212 |
|
| 2017 |
Dhanda DS, Guzauskas GF, Carlson JJ, Basu A, Veenstra DL. Are evidence standards different for genomic- vs. clinical-based precision medicine? - A quantitative analysis of individualized warfarin therapy. Clinical Pharmacology and Therapeutics. PMID 28187492 DOI: 10.1002/cpt.663 |
0.211 |
|
| 2005 |
Strassels S, Sullivan S, Blough D, Hazlet T, Maxwell T, Reifsnyder J, Veenstra D. Characterization of pain in persons who received hospice care in the United States (US) The Journal of Pain. 6: S71. DOI: 10.1016/J.Jpain.2005.01.281 |
0.209 |
|
| 2005 |
Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M, Penson D. Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide? Urology. 66: 835-9. PMID 16230148 DOI: 10.1016/j.urology.2005.04.028 |
0.209 |
|
| 2024 |
Lennon NJ, Kottyan LC, Kachulis C, Abul-Husn NS, Arias J, Belbin G, Below JE, Berndt SI, Chung WK, Cimino JJ, Clayton EW, Connolly JJ, Crosslin DR, Dikilitas O, Velez Edwards DR, ... ... Veenstra D, et al. Selection, optimization and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse US populations. Nature Medicine. PMID 38374346 DOI: 10.1038/s41591-024-02796-z |
0.209 |
|
| 2021 |
Bansal A, Heagerty PJ, Inoue LYT, Veenstra DL, Wolock CJ, Basu A. A Value-of-Information Framework for Personalizing the Timing of Surveillance Testing. Medical Decision Making : An International Journal of the Society For Medical Decision Making. 272989X211049213. PMID 34747265 DOI: 10.1177/0272989X211049213 |
0.206 |
|
| 2020 |
Hong S, Veenstra D. PCN153 COST-UTILITY ANALYSIS OF RUXOLITINIB VERSUS BEST AVAILABLE THERAPY FOR THE TREATMENT OF HYDROXYUREA RESISTANT/INTOLERANT POLYCYTHEMIA VERA WITHOUT SPLENOMEGALY IN THE UNITED STATES Value in Health. 23: S50. DOI: 10.1016/j.jval.2020.04.1638 |
0.205 |
|
| 2023 |
Linder JE, Tao R, Chung WK, Kiryluk K, Liu C, Weng C, Connolly JJ, Hakonarson H, Harr M, Leppig KA, Jarvik GP, Veenstra DL, Aufox S, Chisholm RL, Gordon AS, et al. Prospective, multi-site study of healthcare utilization after actionable monogenic findings from clinical sequencing. American Journal of Human Genetics. PMID 37883979 DOI: 10.1016/j.ajhg.2023.10.006 |
0.205 |
|
| 2006 |
Ramsey SD, Veenstra DL, Garrison LP, Carlson R, Billings P, Carlson J, Sullivan SD. Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests. The American Journal of Managed Care. 12: 197-202. PMID 16610921 |
0.203 |
|
| 2019 |
Neuberger E, Veenstra D. PND20 COST-UTILITY OF CANNABIDIOL IN ADDITION TO BACKGROUND THERAPY VERSUS BACKGROUND THERAPY ALONE IN LENNOX-GASTAUT SYNDROME Value in Health. 22: S273. DOI: 10.1016/J.JVAL.2019.04.1293 |
0.203 |
|
| 2021 |
Makhnoon S, Bowen DJ, Shirts BH, Fullerton SM, Larson EB, Ralston JD, Leppig KA, Crosslin DR, Veenstra D, Jarvik GP. The FamilyTalk randomized controlled trial: patient-reported outcomes in clinical genetic sequencing for colorectal cancer. Cancer Causes & Control : Ccc. PMID 33591484 DOI: 10.1007/s10552-021-01398-1 |
0.201 |
|
| 2020 |
Guzauskas GF, Garbett S, Zhou Z, Spencer SJ, Smith HS, Hao J, Hassen D, Snyder SR, Graves JA, Peterson JF, Williams MS, Veenstra DL. Cost-effectiveness of Population-Wide Genomic Screening for Hereditary Breast and Ovarian Cancer in the United States. Jama Network Open. 3: e2022874. PMID 33119106 DOI: 10.1001/jamanetworkopen.2020.22874 |
0.2 |
|
| 2012 |
Bates SM, Greer IA, Middeldorp S, Veenstra D, Prabulos A, Vandvik PO. Screening for Antiphospholipid Antibodies in Women With Pregnancy Complications: Response Chest. 142: 545-546. DOI: 10.1378/Chest.12-0948 |
0.196 |
|
| 2023 |
Guzauskas GF, Garbett S, Zhou Z, Schildcrout JS, Graves JA, Williams MS, Hao J, Jones LK, Spencer SJ, Jiang S, Veenstra DL, Peterson JF. Population Genomic Screening for Three Common Hereditary Conditions : A Cost-Effectiveness Analysis. Annals of Internal Medicine. PMID 37155986 DOI: 10.7326/M22-0846 |
0.196 |
|
| 2008 |
Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: A cost-effectiveness analysis (Alimentary Pharmacology and Therapeutic (2008) 27, (1240-1252)) Alimentary Pharmacology and Therapeutics. 28: 166. DOI: 10.1111/j.1365-2036.2008.03743.x |
0.19 |
|
| 2020 |
Jiao B, Veenstra DL, Lee W, Carlson JJ, Devine B. The use of real-world evidence in ICER's scoping process and clinical evidence assessments. Journal of Managed Care & Specialty Pharmacy. 26: 1590-1595. PMID 33251999 DOI: 10.18553/jmcp.2020.26.12.1590 |
0.189 |
|
| 2010 |
Veenstra DL. The role of epidemiology in assessing the potential clinical impact of pharmacogenomics Human Genome Epidemiology: Building the Evidence For Using Genetic Information to Improve Health and Prevent Disease: Second Edition. DOI: 10.1093/acprof:oso/9780195398441.003.0027 |
0.189 |
|
| 2023 |
Rao ND, King KM, Kaganovsky J, Hassan S, Tsinajinne D, Fullerton SM, Chen AT, Veenstra DL, Shirts BH. Risk perception and intended behavior change after uninformative genetic results for adult-onset hereditary conditions in unselected patients. European Journal of Human Genetics : Ejhg. PMID 37752309 DOI: 10.1038/s41431-023-01460-3 |
0.189 |
|
| 2021 |
Neuberger EE, Carlson JJ, Veenstra DL. Authors' Reply to Comment on "Cost-Effectiveness of Cannabidiol Adjunct Therapy Versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome". Pharmacoeconomics. PMID 33674997 DOI: 10.1007/s40273-021-01006-9 |
0.187 |
|
| 2023 |
Guo B, Knerr S, Kauffman TL, Mittendorf KF, Keast E, Gilmore MJ, Feigelson HS, Lynch FL, Muessig KR, Okuyama S, Zepp JM, Veenstra DL, Hsu L, Phipps AI, Lindström S, et al. Risk management actions following genetic testing in the Cancer Health Assessments Reaching Many (CHARM) Study: A prospective cohort study. Cancer Medicine. PMID 37644850 DOI: 10.1002/cam4.6485 |
0.186 |
|
| 2000 |
Phillips KA, Veenstra DL, Sadee W. Implications of the genetics revolution for health services research: pharmacogenomics and improvements in drug therapy. Health Services Research. 35: 128-40. PMID 16148957 |
0.186 |
|
| 2002 |
Phillips K, Veenstra D, Oren E, Lee J, Sadee W. PHP35 ANALYZING THE CLINICAL, ECONOMIC, AND POLICY IMPACT OF INDIVIDUALIZED MEDICINE BASED ON GENETIC INFORMATION (“PHARMACOGENOMICS“) Value in Health. 5: 152. DOI: 10.1016/S1098-3015(10)60895-9 |
0.182 |
|
| 2023 |
Lennon NJ, Kottyan LC, Kachulis C, Abul-Husn N, Arias J, Belbin G, Below JE, Berndt S, Chung W, Cimino JJ, Clayton EW, Connolly JJ, Crosslin D, Dikilitas O, Velez Edwards DR, ... ... Veenstra D, et al. Selection, optimization, and validation of ten chronic disease polygenic risk scores for clinical implementation in diverse populations. Medrxiv : the Preprint Server For Health Sciences. PMID 37333246 DOI: 10.1101/2023.05.25.23290535 |
0.181 |
|
| 2020 |
Basit A, Estergreen JK, Sabath DE, Veenstra D, Hopkins S, Boyer B, Rettie A, Thummel K, Prasad B. P195 - A novel LC-MS/MS method for pivkaii quantification: Characterization of warfarin induced altered prothrombin des-carboxylation Drug Metabolism and Pharmacokinetics. 35. DOI: 10.1016/J.Dmpk.2020.04.196 |
0.179 |
|
| 2018 |
Li M, Bennette CS, Amendola LM, Ragan Hart M, Heagerty P, Comstock B, Tarczy-Hornoch P, Fullerton SM, Regier DA, Burke W, Trinidad SB, Jarvik GP, Veenstra DL, Patrick DL. The Feelings About genomiC Testing Results (FACToR) Questionnaire: Development and Preliminary Validation. Journal of Genetic Counseling. PMID 30173308 DOI: 10.1007/s10897-018-0286-9 |
0.177 |
|
| 2015 |
Bennette CS, Burke W, Jarvik GP, Veenstra DL. Response to Phillips et al. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 17: 315. PMID 25835196 DOI: 10.1038/Gim.2015.11 |
0.173 |
|
| 2022 |
Guzauskas GF, Jiang S, Garbett S, Zhou Z, Spencer SJ, Snyder SR, Graves JA, Williams MS, Hao J, Peterson JF, Veenstra DL. Cost-effectiveness of population-wide genomic screening for Lynch syndrome in the United States. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 35227606 DOI: 10.1016/j.gim.2022.01.017 |
0.173 |
|
| 2017 |
Ali M, MacIsaac R, Quinn TJ, Bath PM, Veenstra DL, Xu Y, Brady MC, Patel A, Lees KR. Dependency and health utilities in stroke: Data to inform cost-effectiveness analyses. European Stroke Journal. 2: 70-76. PMID 30009266 DOI: 10.1177/2396987316683780 |
0.167 |
|
| 2024 |
Wong W, Kowal S, To TM, Patel A, Veenstra D, Garrison L, Li M. The value of the accelerated approval pathway: real-world outcomes associated with reducing the time between innovations. Future Oncology (London, England). PMID 38258557 DOI: 10.2217/fon-2023-0514 |
0.166 |
|
| 2021 |
Smith HS, Brothers KB, Knight SJ, Ackerman SL, Rini C, Veenstra DL, McGuire AL, Wilfond BS, Malek J. Conceptualization of utility in translational clinical genomics research. American Journal of Human Genetics. 108: 2027-2036. PMID 34687653 DOI: 10.1016/j.ajhg.2021.08.013 |
0.166 |
|
| 2023 |
Knerr S, Guo B, Wernli KJ, Mittendorf KF, Feigelson HS, Gilmore MJ, Jarvik GP, Kauffman TL, Keast E, Liles EG, Lynch FL, Muessig KR, Okuyama S, Veenstra DL, Zepp JM, et al. Longitudinal adherence to breast cancer surveillance following cancer genetic testing in an integrated health care system. Breast Cancer Research and Treatment. PMID 37470892 DOI: 10.1007/s10549-023-07007-w |
0.165 |
|
| 2019 |
Hart MR, Biesecker BB, Blout CL, Christensen KD, Amendola LM, Bergstrom KL, Biswas S, Bowling KM, Brothers KB, Conlin LK, Cooper GM, Dulik MC, East KM, Everett JN, Finnila CR, ... ... Veenstra DL, et al. Correction: Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite study. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 30670880 DOI: 10.1038/s41436-019-0440-2 |
0.165 |
|
| 2022 |
Knerr S, Guo B, Mittendorf KF, Feigelson HS, Gilmore MJ, Jarvik GP, Kauffman TL, Keast E, Lynch FL, Muessig KR, Okuyama S, Veenstra DL, Zepp JM, Goddard KAB, Devine B. Risk-reducing surgery in unaffected individuals receiving cancer genetic testing in an integrated health care system. Cancer. PMID 35679147 DOI: 10.1002/cncr.34349 |
0.164 |
|
| 2021 |
Chen S, Graff J, Yun S, Beal B, Ta JT, Bansal A, Carlson JJ, Veenstra DL, Basu A, Devine B. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making. Journal of Managed Care & Specialty Pharmacy. 27: 95-104. PMID 33377442 DOI: 10.18553/jmcp.2021.27.1.095 |
0.159 |
|
| 2021 |
Veenstra DL, Rowe JW, Pagán JA, Brown HS, Schneider JE, Gupta A, Berger SM, Chung WK, Appelbaum PS. Reimbursement for genetic variant reinterpretation: five questions payers should ask. The American Journal of Managed Care. 27: e336-e338. PMID 34668674 DOI: 10.37765/ajmc.2021.88763 |
0.155 |
|
| 2008 |
Cooper GM, Johnson JA, Langaee TY, Feng H, Stanaway IB, Schwarz UI, Ritchie MD, Stein CM, Roden DM, Smith JD, Veenstra DL, Rettie AE, Rieder MJ. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood. 112: 1022-7. PMID 18535201 DOI: 10.1182/Blood-2008-01-134247 |
0.155 |
|
| 2017 |
Kuderer NM, Burton KA, Blau S, Senecal F, Gadi VK, Parker S, Mahen E, Veenstra D, Carlson JJ, Lyman GH, Blau CA. Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer. Jco Precision Oncology. 1. PMID 32913975 DOI: 10.1200/PO.17.00076 |
0.149 |
|
| 2021 |
Rodriguez PJ, Veenstra DL, Heagerty PJ, Goss CH, Ramos KJ, Bansal A. A Framework for Using Real-World Data and Health Outcomes Modeling to Evaluate Machine Learning-Based Risk Prediction Models. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 25: 350-358. PMID 35227445 DOI: 10.1016/j.jval.2021.11.1360 |
0.148 |
|
| 2014 |
Roth JA, Boudreau D, Fujii MM, Farin FM, Rettie AE, Thummel KE, Veenstra DL. Genetic risk factors for major bleeding in patients treated with warfarin in a community setting. Clinical Pharmacology and Therapeutics. 95: 636-43. PMID 24503627 DOI: 10.1038/Clpt.2014.26 |
0.147 |
|
| 2022 |
Kim E, Marcum ZA, Raimundo K, Veenstra DL. Health care utilization and expenditures of parents of children with and without hemophilia A. Journal of Managed Care & Specialty Pharmacy. 28: 529-537. PMID 35471073 DOI: 10.18553/jmcp.2022.28.5.529 |
0.147 |
|
| 2023 |
Linder JE, Allworth A, Bland ST, Caraballo PJ, Chisholm RL, Clayton EW, Crosslin DR, Dikilitas O, DiVietro A, Esplin ED, Forman S, Freimuth RR, Gordon AS, Green R, Harden MV, ... ... Veenstra D, et al. Returning integrated genomic risk and clinical recommendations: the eMERGE study. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 100006. PMID 36621880 DOI: 10.1016/j.gim.2023.100006 |
0.146 |
|
| 2021 |
Wong WB, To TM, Li M, Lee W, Veenstra DL, Garrison LP. Real-world evidence for option value in metastatic melanoma. Journal of Managed Care & Specialty Pharmacy. 1-10. PMID 34431715 DOI: 10.18553/jmcp.2021.21192 |
0.145 |
|
| 2022 |
Lee W, Wong WB, Kowal S, Garrison LP, Veenstra DL, Li M. Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung Cancer. Pharmacoeconomics. PMID 35527331 DOI: 10.1007/s40273-022-01147-5 |
0.145 |
|
| 2022 |
Spencer SJ, Jones LK, Guzauskas GF, Hao J, Williams MS, Peterson JF, Veenstra DL. Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States. Journal of Clinical Lipidology. PMID 35961838 DOI: 10.1016/j.jacl.2022.07.014 |
0.145 |
|
| 2002 |
Chaiyakunapruk N, Veenstra DL, Lipsky BA, Saint S. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Annals of Internal Medicine. 136: 792-801. PMID 12044127 |
0.145 |
|
| 2023 |
Lee W, Carlson JJ, Basu A, Veenstra D. Quantifying the value of older adult-specific clinical trials: Post-lumpectomy irradiation among older adults with early-stage breast cancer. Journal of Geriatric Oncology. 14: 101487. PMID 37075565 DOI: 10.1016/j.jgo.2023.101487 |
0.14 |
|
| 2020 |
Guo H, Veenstra D. PCN59 HOW IMPORTANT IS FAMILY COMMUNICATION IN LYNCH SYNDROME SCREENING? A COST-EFFECTIVENESS THRESHOLD ANALYSIS OF A FAMILY COMMUNICATION TOOL FOR COLORECTAL CANCER PATIENTS POSITIVE FOR LYNCH SYNDROME AND THEIR FIRST-DEGREE RELATIVES Value in Health. 23: S33. DOI: 10.1016/j.jval.2020.04.1562 |
0.136 |
|
| 2022 |
Smith HS, Bonkowski ES, Deloge RB, Gutierrez AM, Recinos AM, Lavelle TA, Veenstra DL, McGuire AL, Pereira S. Key drivers of family-level utility of pediatric genomic sequencing: a qualitative analysis to support preference research. European Journal of Human Genetics : Ejhg. PMID 36434257 DOI: 10.1038/s41431-022-01245-0 |
0.127 |
|
| 2005 |
Penson DF, Ramsey S, Veenstra D, Clarke L, Gandhi S, Hirsch M. The cost-effectiveness of combined androgen blockade with bicalutamide and luteinizing hormone releasing hormone agonist in men with metastatic prostate cancer. The Journal of Urology. 174: 547-52; discussion 5. PMID 16006889 DOI: 10.1097/01.ju.0000165569.48372.4c |
0.127 |
|
| 2019 |
Kim E, Brouwer E, Veenstra D. PNS177 A SYSTEMATIC REVIEW AND CONTENT ANALYSIS OF RHETORIC ABOUT THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW (ICER) IN THE WRITTEN MEDIA, 2015-2017 Value in Health. 22: S315. DOI: 10.1016/J.JVAL.2019.04.1534 |
0.125 |
|
| 2021 |
Bowen DJ, Makhnoon S, Shirts BH, Fullerton SM, Larson E, Ralston JD, Leppig K, Crosslin DR, Veenstra D, Jarvik GP. What improves the likelihood of people receiving genetic test results communicating to their families about genetic risk? Patient Education and Counseling. PMID 33455827 DOI: 10.1016/j.pec.2021.01.001 |
0.125 |
|
| 2016 |
Bennette CS, Ramsey SD, McDermott CL, Carlson JJ, Basu A, Veenstra DL. Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials. Journal of the National Cancer Institute. 108. PMID 26714555 DOI: 10.1093/jnci/djv324 |
0.124 |
|
| 2021 |
Lee W, Li M, Wong WB, To TM, Garrison LP, Veenstra DL. Modeling the Ex Post Real Option Value in Metastatic Melanoma Using Real-World Data. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 24: 1746-1753. PMID 34838272 DOI: 10.1016/j.jval.2021.07.004 |
0.122 |
|
| 2005 |
Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. The New England Journal of Medicine. 352: 2285-93. PMID 15930419 DOI: 10.1056/Nejmoa044503 |
0.122 |
|
| 2008 |
Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, ... ... Veenstra DL, et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clinical Pharmacology and Therapeutics. 84: 326-31. PMID 18305455 DOI: 10.1038/Clpt.2008.10 |
0.121 |
|
| 2020 |
Hendrix N, Hauber B, Lee CI, Bansal A, Veenstra DL. Artificial intelligence in breast cancer screening: primary care provider preferences. Journal of the American Medical Informatics Association : Jamia. PMID 33367670 DOI: 10.1093/jamia/ocaa292 |
0.121 |
|
| 2007 |
Strassels S, Blough D, Veenstra D, Hazlet T, Sullivan S. (916) The Journal of Pain. 8: S80. DOI: 10.1016/j.jpain.2007.02.324 |
0.12 |
|
| 2022 |
Jones LK, Chen N, Hassen D, McMinn M, Klinger T, Hartzel DN, Veenstra D, Spencer S, Snyder SR, Peterson JF, Schlieder V, Sturm AC, Gidding SS, Williams MS, Hao J. Impact of a Population Genomic Screening Program on Health Behaviors Related to Familial Hypercholesterolemia Risk Reduction. Circulation. Genomic and Precision Medicine. 101161CIRCGEN1210035. PMID 35862023 DOI: 10.1161/CIRCGEN.121.003549 |
0.118 |
|
| 2013 |
Veenstra DL. Economic Issues and Genomic Medicine Genomic and Personalized Medicine. 1: 440-446. DOI: 10.1016/B978-0-12-382227-7.00039-2 |
0.117 |
|
| 2010 |
Veenstra DL, Garrison LP, Ramsey SD. Economic Issues and Genomic Medicine Essentials of Genomic and Personalized Medicine. 233-244. DOI: 10.1016/B978-0-12-374934-5.00020-9 |
0.117 |
|
| 2023 |
Lee W, Basu A, Carlson JJ, Veenstra D. How does cumulative evidence from older adult-specific trials influence clinical practice? A difference-in-differences analysis in early-stage breast cancer. Contemporary Clinical Trials. 107135. PMID 36868347 DOI: 10.1016/j.cct.2023.107135 |
0.117 |
|
| 2005 |
Veenstra DL, You JHS, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population Pharmacogenetics and Genomics. 15: 687-691. PMID 16141794 DOI: 10.1097/01.Fpc.0000174789.77614.68 |
0.117 |
|
| 2001 |
Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: A systematic review Journal of the American Medical Association. 286: 2270-2279. PMID 11710893 DOI: 10.1001/Jama.286.18.2270 |
0.116 |
|
| 2008 |
Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, Ridker PM, Milligan PE, Grice G, Lenzini P, Rettie AE, Aquilante CL, Grosso L, Marsh S, Langaee T, Farnett LE, ... ... Veenstra DL, et al. Corrigendum: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin (Clinical Pharmacology Therapeutics (2008) 84, (326-331) DOI: 10.1038/clpt.2008.10) Clinical Pharmacology and Therapeutics. 84: 430. DOI: 10.1038/clpt.2008.112 |
0.115 |
|
| 2014 |
Khandelwal N, Hough CL, Bansal A, Veenstra DL, Treggiari MM. Long-term survival in patients with severe acute respiratory distress syndrome and rescue therapies for refractory hypoxemia*. Critical Care Medicine. 42: 1610-8. PMID 24732240 DOI: 10.1097/01.Sa.0000460945.67933.F1 |
0.114 |
|
| 2010 |
Carlson JJ, Sullivan SD, Garrison LP, Neumann PJ, Veenstra DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy (Amsterdam, Netherlands). 96: 179-90. PMID 20226559 DOI: 10.1016/J.Healthpol.2010.02.005 |
0.11 |
|
| 2023 |
Sandin R, Veenstra DL, Vankelegom M, Dzingina M, Sullivan SD, Campbell D, Ma C, Harrison C, Draica F, Wiemken TL, Mugwagwa T. Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States. Journal of Managed Care & Specialty Pharmacy. 29: 1290-1302. PMID 38058141 DOI: 10.18553/jmcp.2023.29.12.1290 |
0.11 |
|
| 2008 |
Garrison LP, Cirrincione A, Weisgerber-Kriegl U, Veenstra DL. Estimating the potential economic value of trastuzumab in breast cancer from 2000–2020 in five European countries Journal of Clinical Oncology. 26: 6611-6611. DOI: 10.1200/JCO.2008.26.15_SUPPL.6611 |
0.106 |
|
| 2022 |
Lee W, Basu A, Carlson JJ, Veenstra D. Can we predict trial failure among older adult-specific clinical trials using trial-level factors? Journal of Geriatric Oncology. PMID 36437194 DOI: 10.1016/j.jgo.2022.11.003 |
0.105 |
|
| 2022 |
Angelo F, Veenstra D, Knerr S, Devine B. Prevalence and prediction of medical distrust in a diverse medical genomic research sample. Genetics in Medicine : Official Journal of the American College of Medical Genetics. PMID 35384843 DOI: 10.1016/j.gim.2022.03.007 |
0.102 |
|
| 1973 |
Veenstra DL, Bambas EJ. Analyzing vehicle impact test data Proceedings of Spie - the International Society For Optical Engineering. 34: 85-94. DOI: 10.1117/12.953646 |
0.101 |
|
| 2022 |
Li M, Garrison L, Lee W, Kowal S, Wong W, Veenstra D. A Pragmatic Guide to Assessing Real Option Value for Medical Technologies. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. PMID 35752536 DOI: 10.1016/j.jval.2022.05.014 |
0.096 |
|
| 2021 |
Saldarriaga EM, Hauber B, Carlson JJ, Barthold D, Veenstra DL, Devine B. Assessing Payers' Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 25: 443-450. PMID 35227457 DOI: 10.1016/j.jval.2021.09.016 |
0.093 |
|
| 1999 |
Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: A meta-analysis Journal of the American Medical Association. 281: 261-267. PMID 9918482 DOI: 10.1001/JAMA.281.3.261 |
0.089 |
|
| 2022 |
Park JY, Veenstra DL, Wallick CJ, Marcum ZA. Prescribing Alzheimer's Disease treatments by provider type and geographic region: a comparison among physicians, nurse practitioners, and physician assistants. Bmc Geriatrics. 22: 522. PMID 35752783 DOI: 10.1186/s12877-022-03176-3 |
0.084 |
|
| 2023 |
Peterson JF, Veenstra DL, Williams MS, Hao J, Guzauskas GF. Population Genomic Screening for Three Common Hereditary Conditions. Annals of Internal Medicine. 176: eL230322. PMID 37983801 DOI: 10.7326/L23-0322 |
0.078 |
|
| 2002 |
Kurre HA, Ettinger AG, Veenstra DL, Gaynon PS, Franklin J, Sencer SF, Reaman GH, Lange BJ, Holcenberg JS. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-1962). Journal of Pediatric Hematology/Oncology. 24: 175-81. PMID 11990302 DOI: 10.1097/00043426-200203000-00004 |
0.077 |
|
| 2004 |
Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. Journal of Clinical Gastroenterology. 38: S158-68. PMID 15602165 |
0.07 |
|
| 2006 |
Strassels SA, Blough DK, Hazlet TK, Veenstra DL, Sullivan SD. Pain, demographics, and clinical characteristics in persons who received hospice care in the United States. Journal of Pain and Symptom Management. 32: 519-31. PMID 17157754 DOI: 10.1016/j.jpainsymman.2006.06.005 |
0.069 |
|
| 1968 |
Veenstra DL. Collision simulation using the GM proving ground impact sled Sae Technical Papers. DOI: 10.4271/680482 |
0.067 |
|
| 2013 |
Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. Recommendations for prophylaxis of pregnancy-related venous thromboembolism in carriers of inherited thrombophilia. Comment on the 2012 ACCP guidelines: A rebuttal Journal of Thrombosis and Haemostasis. 11: 1782-1784. PMID 23819793 DOI: 10.1111/jth.12347 |
0.065 |
|
| 2004 |
Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Archives of Internal Medicine. 164: 994-1003. PMID 15136309 DOI: 10.1001/archinte.164.9.994 |
0.065 |
|
| 1992 |
Mendel D, Ellman JA, Chang Z, Veenstra DL, Kollman PA, Schultz PG. Probing protein stability with unnatural amino acids. Science (New York, N.Y.). 256: 1798-802. PMID 1615324 DOI: 10.1126/Science.1615324 |
0.054 |
|
| 2005 |
Tai G, Farin F, Rieder MJ, Dreisbach AW, Veenstra DL, Verlinde CL, Rettie AE. In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenetics and Genomics. 15: 475-81. PMID 15970795 DOI: 10.1097/01.Fpc.0000162005.80857.98 |
0.052 |
|
| 1995 |
The THP, Veenstra DL, Beck JP. Global modelling of atmospheric trace gases: Application of a global three dimensional model Studies in Environmental Science. 65: 255-260. DOI: 10.1016/S0166-1116(06)80207-4 |
0.051 |
|
| 1997 |
Veenstra DL, Kollman PA. Modeling protein stability: a theoretical analysis of the stability of T4 lysozyme mutants. Protein Engineering. 10: 789-807. PMID 9342145 DOI: 10.1093/Protein/10.7.789 |
0.046 |
|
| 2021 |
Bounthavong M, Christopher MLD, Veenstra DL, Basu A, Devine EB. Exploring Providers' Perception to Naloxone Education for Opioid Overdose After Receiving Academic Detailing at the U.S. Department of Veterans Affairs. Journal of Pharmacy Practice. 8971900211053282. PMID 34766510 DOI: 10.1177/08971900211053282 |
0.042 |
|
| 1996 |
Sun YC, Veenstra DL, Kollman PA. Free energy calculations of the mutation of Ile96-->Ala in barnase: contributions to the difference in stability. Protein Engineering. 9: 273-81. PMID 8736494 DOI: 10.1093/Protein/9.3.273 |
0.036 |
|
| 1992 |
Veenstra DL, Ferguson DM, Kollman PA. How transferable are hydrogen parameters in molecular mechanics calculations? Journal of Computational Chemistry. 13: 971-978. DOI: 10.1002/Jcc.540130807 |
0.034 |
|
| 1994 |
Cornish VW, Kaplan MI, Veenstra DL, Kollman PA, Schultz PG. Stabilizing and destabilizing effects of placing beta-branched amino acids in protein alpha-helices. Biochemistry. 33: 12022-31. PMID 7918421 DOI: 10.1021/Bi00206A003 |
0.031 |
|
| 1998 |
Wang L, Veenstra DL, Radmer RJ, Kollman PA. Can one predict protein stability? An attempt to do so for residue 133 of T4 lysozyme using a combination of free energy derivatives, PROFEC, and free energy perturbation methods. Proteins. 32: 438-58. PMID 9726415 DOI: 10.1002/(Sici)1097-0134(19980901)32:4<438::Aid-Prot4>3.0.Co;2-C |
0.026 |
|
| 1998 |
Veenstra DL, Gerig JT. Fluorine NMR studies of the human carbonic anhydrase-3,5-difluorobenzenesulfonamide complex Magnetic Resonance in Chemistry. 36: S169-S178. |
0.015 |
|
| 2010 |
MENDEL D, ELLMAN JA, CHANG Z, VEENSTRA DL, KOLLMAN PA, SCHULTZ PG. ChemInform Abstract: Probing Protein Stability with Unnatural Amino Acids. Cheminform. 24: no-no. DOI: 10.1002/chin.199306275 |
0.01 |
|
| 1992 |
Jacobson AR, Sylvia LA, Veenstra DL, Gerig JT. 19F[1H] NOE determinations in surface-coil experiments Journal of Magnetic Resonance (1969). 96: 387-392. DOI: 10.1016/0022-2364(92)90092-L |
0.01 |
|
| Hide low-probability matches. |